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During	  the	  mid	  to	  late	  1990’s,	  nearly	  all	  HIV	  infected	  children	  admitted	  to	  South	  African	  
paediatric	  intensive	  care	  units	  died.	  This	  was	  in	  the	  context	  of	  an	  increasing	  HIV	  epidemic	  in	  
Sub-­‐Saharan	  Africa,	  a	  limited	  number	  of	  intensive	  care	  beds	  in	  public	  hospitals	  and	  the	  South	  
African	  government	  refusing	  to	  supply	  antiretroviral	  medication	  to	  public	  sector	  patients.	  HIV	  
infected	  children	  all	  die	  without	  ARV	  medication,	  and	  it	  resulted	  in	  an	  increase	  in	  the	  South	  
African	  under-­‐5	  mortality	  rate.	  In	  this	  context	  critically	  ill	  HIV	  infected	  children	  were	  often	  
denied	  PICU	  admission.	  Developed	  countries	  introduced	  ARV	  medication	  in	  the	  early	  1990’s	  
and	  the	  South	  African	  government	  only	  started	  supplying	  ARV	  medication	  in	  late	  2003.	  
When	  ARV	  medication	  became	  available	  in	  South	  Africa,	  it	  was	  started	  on	  the	  basis	  of	  the	  
individual	  child’s	  clinical	  and	  immunological	  status	  and	  there	  was	  not	  much	  published	  data	  on	  
initiation	  of	  ARV	  therapy	  in	  critical	  ill	  children	  in	  intensive	  care	  units.	  Many	  HIV	  infected	  
children	  had	  recurrent	  hospital	  admissions	  and	  many	  children	  died	  before	  initiating	  ARV	  
medication.	  HIV	  infected	  children	  are	  not	  only	  susceptible	  to	  the	  normal	  bacteria	  and	  viruses,	  
but	  at	  increased	  risk	  of	  opportunistic	  and	  mycobacterial	  infections.	  CMV	  has	  increasingly	  been	  
recognized	  as	  a	  common	  co-­‐infection	  with	  PCP,	  but	  has	  been	  difficult	  to	  diagnose	  and	  treat	  
effectively.	  
We	  retrospectively	  reviewed	  all	  HIV	  exposed	  and	  infected	  children	  admitted	  to	  our	  PICU	  in	  
2009.	  In	  addition	  to	  our	  standard	  treatment,	  we	  initiated	  ARV	  medication	  as	  soon	  as	  logistically	  
possible	  and	  children	  with	  suspected	  CMV	  infections	  were	  empirically	  treated	  with	  gancyclovir.	  
There	  were	  1231	  PICU	  admissions	  during	  the	  1-­‐year	  study	  period,	  with	  144	  (11.7%)	  deaths.	  
The	  standardized	  mortality	  ratio	  (PIM2)	  was	  0.74.	  There	  were	  123	  HIV	  related	  admissions;	  75	  
HIV	  infected	  children	  had	  85	  admissions,	  there	  were	  24	  HIV	  exposed	  but	  HIV	  negative	  
admissions	  and	  14	  HIV	  exposed	  children	  had	  no	  confirmatory	  tests.	  Respiratory	  failure	  was	  the	  
main	  reason	  for	  PICU	  admission	  in	  68%	  of	  cases.	  Only	  29%	  of	  HIV	  infected	  children	  were	  
known	  to	  have	  received	  PMTCT.	  HIV	  infected	  children	  had	  a	  median	  age	  of	  4	  months	  (IQR	  3-­‐7),	  
were	  admitted	  for	  a	  median	  of	  6	  days	  (IQR	  3-­‐12)	  and	  spent	  a	  median	  of	  16	  days	  (IQR	  9-­‐28)	  in	  
hospital	  after	  PICU	  discharge.	  On	  admission,	  24	  children	  were	  on	  ARV	  medication	  and	  31	  
children	  (61%	  of	  the	  children	  eligible	  for	  ARV	  medication)	  commenced	  ARV’s	  on	  PICU.	  The	  PCP	  
immunofluorescence	  test	  was	  positive	  in	  25%	  of	  children	  not	  on	  ARV’s.	  Thirty-­‐eight	  percent	  of	  
children	  admitted	  on	  ARV’s	  and	  57%	  of	  the	  HIV	  infected	  children	  not	  on	  ARV’s	  on	  admission	  
had	  a	  CMV	  viral	  load	  >	  log	  4	  copies/ml.	  Fourteen	  (29%)	  children	  who	  started	  ARV’s	  during	  the	  
admission	  developed	  IRIS.	  Seventy-­‐nine	  percent	  of	  HIV	  infected	  children	  survived	  to	  PICU	  
discharge	  and	  69%	  of	  children	  survived	  to	  hospital	  discharge.	  Thirty-­‐one	  HIV	  infected	  children,	  
which	  is	  60%	  of	  the	  children	  discharged	  home,	  or	  89%	  of	  the	  children	  with	  follow	  up	  data,	  
were	  known	  to	  be	  alive	  1	  year	  later.	  
Conclusions:	  	  	  
This	  retrospective	  study	  shows	  that	  increasing	  numbers	  of	  critically	  ill	  HIV	  infected	  children	  
are	  surviving	  PICU	  and	  hospital	  admissions.	  Antiretroviral	  therapy	  was	  successfully	  initiated	  in	  
PICU	  and	  apart	  from	  the	  risk	  of	  IRIS,	  there	  were	  no	  obvious	  side	  effects	  to	  commencing	  ARV’s	  in	  
critically	  ill	  children.	  CMV	  is	  a	  common	  opportunistic	  infection	  in	  HIV	  infected	  children	  and	  
empiric	  therapy	  with	  Gancyclovir	  should	  be	  considered	  whilst	  confirmatory	  blood	  results	  are	  
awaited.	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Part	  A:	  Protocol	  
	  
Outcomes	  of	  Human	  Immunodeficiency	  Virus	  infected	  children	  admitted	  to	  
a	  Paediatric	  Intensive	  Care	  Unit	  in	  Cape	  Town,	  South	  Africa	  
	  
Introduction:	  	  
The	  World	  Health	  Organization	  and	  the	  joint	  United	  Nations	  programme	  on	  HIV/AIDS	  
(UNAIDS)	  estimated	  that	  in	  2009,	  there	  were	  2.5	  million	  Human	  immunodeficiency	  virus	  (HIV)	  
infected	  children	  in	  the	  world,	  with	  2.3	  million	  or	  92%	  of	  these	  children	  living	  in	  Sub-­‐Saharan	  
Africa(1)	  .	  	  
The	  survival	  of	  critically	  ill	  HIV	  infected	  children	  has	  changed	  dramatically	  over	  the	  past	  20	  
years.	  In	  the	  mid	  to	  late	  1990’s,	  nearly	  all	  HIV	  infected	  children	  admitted	  to	  paediatric	  intensive	  
care	  units	  in	  South	  Africa	  (PICU’s)	  died	  (2,3).	  There	  were	  also	  reports	  that	  the	  mortality	  of	  HIV	  
infected	  children	  was	  similar	  with	  and	  without	  the	  availability	  of	  intensive	  care	  treatment	  (4).	  
This	  was	  in	  the	  context	  of	  a	  growing	  HIV	  epidemic	  (5,6),	  a	  limited	  number	  of	  PICU	  beds	  in	  state	  
hospitals	  (7)	  and	  the	  refusal	  of	  the	  South	  African	  government	  to	  supply	  anti-­‐retroviral	  
medication	  to	  public	  sector	  patients	  (8,9).	  This	  resulted	  in	  many	  units	  refusing	  admission	  to	  
HIV	  infected	  children	  with	  life-­‐threatening	  illnesses.	  With	  the	  passage	  of	  time	  and	  increased	  
understanding	  of	  disease	  processes,	  PICU’s	  have	  subsequently	  reported	  survival	  rates	  of	  >70%	  
of	  HIV	  infected	  children	  (10,11).	  	  	  
	  
This	  improved	  survival	  can	  be	  attributed	  to	  a	  number	  of	  factors;	  effective	  treatment	  of	  
Pneumocystis	  jirovecci	  pneumonia	  (PCP),	  the	  availability	  of	  anti-­‐retroviral	  (ARV)	  drugs	  and	  
improvements	  in	  the	  management	  strategies	  and	  technology	  available	  to	  treat	  critically	  ill	  
children	  with	  septic	  shock	  and	  acute	  respiratory	  distress	  syndrome	  (12).	  
	  
	   ii	  
	  
The	  optimal	  time	  for	  starting	  ARV’s	  has	  not	  been	  determined,	  but	  recent	  research	  has	  clearly	  
shown	  improved	  survival	  from	  early	  initiation	  of	  ARV	  therapy.	  The	  Children	  with	  HIV	  Early	  
Antiretroviral	  Therapy	  CHER	  study	  group	  was	  able	  to	  demonstrate	  a	  76%	  reduction	  in	  
mortality	  and	  75%	  reduction	  in	  HIV	  progression	  by	  early	  diagnosis	  of	  HIV	  with	  immediate	  
commencement	  of	  ARV	  therapy	  (13).	  	  
	  
The	  majority	  of	  children	  currently	  commence	  ARV	  therapy	  from	  outpatient	  clinics	  or	  hospital	  
wards.	  There	  is	  very	  little	  data	  on	  the	  initiation	  of	  ARV’s	  in	  critically	  ill	  children.	  The	  hesitancy	  
in	  initiating	  ARV	  medication	  in	  critically	  ill	  children	  was	  related	  to	  the	  fact	  that	  ARV	  medication	  
is	  thought	  not	  to	  improve	  the	  child’s	  condition	  immediately	  and	  there	  is	  potential	  for	  drug	  
toxicity	  in	  critically	  ill	  children	  (14).	  An	  additional	  concern	  about	  starting	  ARV’s	  in	  acutely	  ill	  
children	  is	  the	  potential	  for	  developing	  immune	  reconstitution	  inflammatory	  syndrome	  (IRIS).	  
The	  incidence	  of	  IRIS	  in	  children	  starting	  ARV’s	  has	  been	  reported	  to	  be	  approximately	  20%,	  
with	  a	  BCG	  reaction	  being	  the	  most	  common	  (15,16).	  
	  
HIV	  infected	  children	  are	  also	  at	  increased	  risk	  of	  Cytomegalovirus	  (CMV)	  infection,	  with	  an	  
increased	  risk	  of	  death	  (17,18).	  	  Goussard	  et	  al	  (19)	  estimated	  the	  incidence	  of	  CMV	  infection	  in	  
HIV	  infected	  children	  admitted	  to	  a	  PICU	  as	  72%,	  whilst	  Zampoli	  et	  al	  (18)	  reported	  a	  CMV	  
incidence	  of	  36%	  in	  HIV	  infected	  children	  hospitalized	  with	  severe	  pneumonia.	  The	  diagnosis	  
of	  CMV	  infection	  is	  not	  easy,	  with	  the	  PP65	  antigen	  test	  having	  a	  high	  false	  negative	  rate	  (19)	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Our	  current	  management	  strategy	  for	  children	  with	  severe	  sepsis	  or	  pneumonia	  and	  suspected	  
HIV	  infection	  includes	  the	  following;	  broad	  spectrum	  antibiotics,	  co-­‐trimoxazole	  and	  
prednisone	  for	  suspected	  PCP,	  and	  since	  2008,	  empiric	  gancyclovir	  treatment	  for	  possible	  CMV	  
infection,	  prior	  to	  confirmation	  of	  an	  elevated	  plasma	  CMV	  viral	  load	  or	  detection	  of	  CMV	  in	  TA	  
or	  BAL,	  as	  well	  as	  initiating	  ARV’s	  as	  early	  as	  possible	  after	  HIV	  infection	  has	  been	  confirmed.	  	  
	  
Aim:	  
To	  report	  the	  1-­‐year	  experience	  of	  initiating	  ARV’s	  and	  the	  empiric	  use	  of	  gancyclovir	  therapy	  
in	  HIV	  infected	  children	  admitted	  to	  our	  PICU	  during	  2009.	  
Specific	  objectives	  are	  to	  report	  on:	  
1. The	  numbers	  of	  HIV	  exposed	  and	  infected	  children	  admitted	  to	  PICU	  
2. The	  reason	  HIV	  exposed/infected	  children	  are	  admitted	  to	  PICU	  
3. The	  proportion	  of	  children	  receiving	  PMTCT	  
4. Incidence	  of	  CMV	  Infection	  in	  HIV	  exposed	  and	  infected	  children	  
5. The	  numbers	  of	  children	  starting	  ARV’s	  in	  PICU	  
6. Complications	  relating	  to	  initiating	  ARV’s	  in	  PICU	  
7. Length	  of	  PICU	  and	  hospital	  stay	  
8. PICU	  and	  hospital	  survival	  rates	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Methodology:	  
	  
All	  HIV	  exposed	  and	  infected	  children	  admitted	  to	  the	  PICU	  during	  2009	  will	  be	  included	  in	  the	  
study.	  HIV	  exposed	  and	  infected	  children	  admitted	  to	  the	  PICU	  during	  2009	  will	  be	  identified	  
from	  the	  intensive	  care	  unit’s	  electronic	  patient	  database	  and	  cross	  referenced	  with	  the	  
hospital’s	  admission	  system.	  	  
	  
The	  following	  investigations	  are	  routinely	  requested	  on	  children	  admitted	  with	  severe	  sepsis	  or	  
pneumonia;	  blood	  culture,	  full	  blood	  count,	  serum	  electrolytes	  and	  renal	  function,	  urinalysis,	  
tracheal	  aspirate	  (TA)	  or	  broncho-­‐alveolar	  lavage	  (BAL)	  for	  respiratory	  viral	  screen	  (multiplex	  
PCR	  kit,	  Seeplex	  RV	  7	  Detection	  kit;	  Seegene,	  Rockville,	  MD),	  microscopy	  and	  culture,	  and	  PCP	  
immune-­‐fluorescence	  testing	  (IF:	  Detect	  IF	  PC,	  Axis-­‐Shield,	  UK).	  	  
	  
Children	  who	  have	  not	  previously	  been	  tested	  for	  HIV	  are	  screened	  with	  an	  HIV	  rapid	  test	  
(Determine	  HIV	  1/2,	  Abbot	  Laboratories,	  Abbot	  Park,	  IL).	  HIV	  infection	  is	  confirmed	  in	  HIV	  
exposed	  children	  with	  an	  HIV	  PCR	  test	  (Amplicor	  HIV-­‐1	  DNA	  test	  version	  1.5,	  Roche	  
Diagnostics,	  GmbH,	  Mannheim,	  Germany)	  if	  they	  are	  under	  18	  months	  and	  with	  an	  HIV	  Elisa	  
test	  (Architect	  HIV	  Ag/Ab	  Combo	  ELISA,	  Abbott	  Laboratories,	  Abbott	  Park,	  IL)	  if	  they	  are	  older	  
than	  18	  months	  of	  age.	  	  
	  
When	  there	  is	  a	  clinical	  concern	  about	  possible	  Mycobacterium	  tuberculosis	  infection,	  a	  
Mantoux	  (purified	  protein	  derivative,	  Statens	  Serum	  Institute,	  Copenhagen,	  Denmark)	  is	  done	  
in	  children	  younger	  than	  7	  years	  and	  either	  gastric	  washings	  or	  tracheal	  aspirates	  are	  sent	  for	  
microscopy	  and	  culture	  	  
	  
Gancyclovir	  is	  started	  empirically	  in	  all	  HIV	  exposed	  and	  infected	  children	  admitted	  with	  severe	  
pneumonia	  or	  suspected	  of	  having	  CMV	  intestinal	  infection.	  A	  systemic	  CMV	  viral	  load	  (Artus	  
	  
	   v	  
RealArt	  LC	  CMV	  PCR,	  Qiagen,	  Germany)	  greater	  than	  4.0	  log	  copies	  /ml,	  is	  considered	  to	  be	  
indicative	  of	  active	  CMV	  infection	  (18,20).	  Gancyclovir	  is	  stopped	  if	  the	  systemic	  CMV	  viral	  load	  
is	  less	  than	  4.0	  log	  copies	  /	  ml.	  	  	  	  
Complications	  thought	  to	  be	  related	  to	  ARV	  drug	  administration	  e.g.	  IRIS,	  will	  be	  recorded	  as	  
per	  treating	  clinicians’	  documentation.	  	  
The	  data	  shown	  in	  Appendix	  1,	  will	  be	  retrospectively	  collected	  from	  the	  intensive	  care	  unit	  
database,	  patient	  folders,	  the	  hospital	  laboratory	  result	  system	  and	  the	  hospital	  patient	  




Data	  will	  be	  stored	  in	  a	  secure	  stata	  file	  and	  data	  analysis	  will	  be	  performed	  using	  Stata	  11,	  
(StataCorp.	  2009.	  College	  Station,	  TX:	  StataCorp	  LP).	  The	  distribution	  of	  numerical	  variables	  
will	  be	  determined	  by	  histograms	  and	  the	  Shapiro-­‐Wilkes	  test.	  Numerical	  variables	  will	  be	  
expressed	  as	  either	  means	  with	  standard	  deviations	  or	  medians	  and	  interquartile	  ranges	  




Approval	  will	  be	  obtained	  from	  the	  Departmental	  Research	  Committee,	  School	  of	  Child	  and	  
Adolescent	  Health,	  the	  Human	  Research	  Ethics	  Committee	  of	  the	  Faculty	  of	  Health	  Sciences,	  
University	  of	  Cape	  Town	  and	  the	  research	  review	  committee	  of	  the	  Red	  Cross	  War	  Memorial	  
Children’s	  Hospital.	  Informed	  consent	  will	  not	  be	  obtained	  from	  patients	  or	  their	  caregivers,	  as	  
this	  is	  a	  retrospective	  audit	  of	  clinical	  practice	  and	  no	  interventions	  are	  planned.	  Patient	  
confidentiality	  will	  be	  maintained	  throughout.	  	  All	  research	  will	  adhere	  to	  the	  requirements	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Potential	  Benefits	  of	  the	  study:	  
	  
Documentation	  of	  the	  PICU	  and	  hospital	  survival	  rates	  with	  1-­‐year	  follow-­‐up.	  The	  response	  to	  
early	  initiation	  of	  ARV’s	  and	  the	  incidence	  of	  CMV	  infection	  in	  critically	  ill	  HIV-­‐infected	  children	  
admitted	  to	  our	  unit.	  
This	  information	  will	  help	  clinicians	  to	  make	  rational	  decisions	  about	  the	  most	  appropriate	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Part	  B:	  	  Structured	  Literature	  review:	  
	  
a) Objectives:	  
The	  aim	  of	  this	  literature	  review	  is	  to	  focus	  on	  the	  following	  management	  aspects	  of	  HIV	  
infected	  children:	  
• Initiation	  of	  ARV’s	  in	  intensive	  care	  and	  critically	  ill	  children	  
• Immune	  reconstitution	  inflammatory	  syndrome	  (IRIS):	  
• The	  prevalence	  of	  CMV	  infection	  in	  HIV	  infected	  children	  
• PICU	  and	  hospital	  survival	  rates	  
	   	  
b) Search	  strategy	  
I	  searched	  Pubmed	  and	  Google	  scholar	  for	  studies	  published	  between	  the	  years	  1990	  and	  
2014.	  The	  search	  was	  done	  using	  both	  keywords	  and	  Medical	  Subject	  Headings	  with	  the	  
following	  terms:	  “HIV”,	  “outcome”,	  “antiretroviral	  therapy”,	  “treatment”,	  “HAART”,	  “CMV”,	  
“Cytomegalovirus”,	  “PCP”,	  “IRIS”,	  “PICU”,	  “intensive	  care”,	  “child”,	  “paediatrics”,	  “pediatrics”,	  	  
I	  also	  searched	  the	  references	  of	  selected	  articles	  and	  included	  relevant	  studies.	  
All	  study	  designs	  were	  included	  and	  articles	  not	  relevant	  to	  the	  literature	  review	  objectives	  
were	  excluded.	  
	  
c) Summary	  and	  interpretation	  of	  literature	  
Initiation	  of	  ARV’s	  in	  intensive	  care	  and	  critically	  ill	  children:	  
The	  2013	  World	  Health	  Organization	  (WHO)	  guidelines	  (1)	  suggested	  that	  all	  HIV	  infected	  
children	  under	  5	  years	  of	  age	  should	  be	  treated	  with	  ARV	  therapy,	  irrespective	  of	  their	  CD4	  
count	  or	  clinical	  stage	  of	  disease.	  The	  question	  of	  when	  to	  start	  ARV	  therapy	  in	  children	  was	  
addressed	  in	  a	  2012	  Cochrane	  Collaboration	  review	  (2),	  examining	  the	  effectiveness	  of	  ARV	  
therapy	  in	  HIV	  infected	  children	  under	  2	  years	  of	  age.	  The	  paucity	  of	  literature	  on	  the	  
subject	  is	  reflected	  by	  the	  inclusion	  of	  only	  2	  articles	  to	  answer	  this	  question.	  	  
	  
	   x	  
	  
The	  Children	  with	  HIV	  Early	  Antiretroviral	  Therapy	  (CHER)	  study	  team	  (3)	  randomized	  HIV	  
infants,	  with	  a	  median	  age	  of	  7.4	  week	  and	  CD4	  percentage	  of	  35%,	  to	  receive	  either	  
immediate	  ARV	  therapy	  or	  deferred	  ARV	  therapy,	  when	  the	  CD4	  percentage	  dropped	  to	  
below	  20%	  (25%	  in	  infants	  under	  1	  year)	  or	  until	  clinical	  criteria	  for	  disease	  progression	  
were	  met.	  The	  study	  included	  125	  infants	  in	  the	  deferred	  ARV	  group	  and	  252	  infants	  
received	  immediate	  ARV	  therapy	  between	  August	  2005	  and	  February	  2007.	  According	  to	  
the	  study	  protocol,	  66%	  (83/125)	  of	  infants	  in	  the	  deferred	  ARV	  group	  commenced	  ARV	  
therapy,	  after	  a	  median	  follow	  up	  period	  of	  40	  weeks.	  There	  were	  20	  infant	  deaths	  (16%)	  in	  
the	  deferred	  ARV	  group	  compared	  to	  10	  infants	  (4%)	  in	  the	  early	  ARV	  group.	  There	  was	  
disease	  progression	  in	  32	  infants	  (26%)	  in	  the	  deferred	  ARV	  group,	  compared	  to	  16	  infants	  
(16%)	  in	  the	  early	  ARV	  treatment	  group.	  The	  study	  was	  stopped	  at	  the	  second	  review	  of	  the	  
data	  and	  safety	  board,	  when	  it	  became	  clear	  that	  in	  this	  study,	  early	  initiation	  of	  ARV	  
treatment	  in	  infants	  reduced	  mortality	  by	  76%	  and	  HIV	  disease	  progression	  by	  75%.	  	  
	  
The	  second	  study	  by	  Prendergast	  et	  al	  (4)	  investigated	  the	  efficacy	  of	  early	  ARV	  therapy	  on	  
viral	  suppression,	  in	  a	  group	  of	  infants	  who	  had	  received	  nevirapine	  perinatally.	  They	  
randomized	  HIV	  infected	  infants	  to	  either	  immediate	  ARV	  therapy	  or	  deferred	  ARV	  therapy,	  
when	  CD4	  counts	  dropped	  below	  20%.	  They	  included	  43	  infants	  in	  the	  immediate	  ARV	  
group	  and	  20	  infants	  in	  the	  deferred	  ARV	  group.	  In	  the	  deferred	  ARV	  group,	  the	  CD4	  counts	  
of	  17	  children	  dropped	  below	  20%	  in	  the	  first	  year	  and	  were	  eligible	  for	  ARV	  treatment.	  1-­‐
year	  post	  initiating	  ARV	  therapy,	  94	  %	  of	  children	  had	  suppressed	  viral	  load	  with	  less	  than	  
50	  copies/ml.	  They	  also	  reported	  that	  infants	  randomized	  to	  receive	  immediate	  ARV	  had	  
significantly	  fewer	  illness	  episodes	  compared	  to	  infants	  in	  the	  deferred	  ARV	  group.	  	  
	  
	  
	   xi	  
Cowburn	  et	  al	  (5)	  reported	  the	  short	  term	  outcomes	  of	  a	  group	  of	  HIV	  infected	  children	  who	  
commenced	  ARV	  therapy	  shortly	  after	  PICU	  discharge.	  	  They	  conducted	  a	  prospective	  
observational	  study	  over	  a	  16-­‐month	  period	  starting	  in	  February	  2003.	  	  They	  screened	  all	  
PICU	  admissions	  and	  confirmed	  HIV	  infection	  in	  68	  children,	  of	  which	  51	  survived	  to	  PICU	  
discharge.	  ARV	  treatment	  was	  commenced	  in	  21	  of	  these	  children.	  Of	  the	  children	  that	  
commenced	  ARV	  treatment,	  3	  died	  in	  the	  wards,	  4	  died	  after	  hospital	  discharge,	  3	  children	  
were	  not	  compliant	  with	  medication	  and	  11	  children	  were	  known	  to	  be	  well	  at	  a	  median	  of	  
350	  days.	  Thirteen	  children	  died	  in	  the	  wards	  prior	  to	  commencing	  ARV’s,	  2	  children	  had	  
previously	  been	  started	  on	  ARV	  therapy	  and	  9	  children	  did	  not	  meet	  the	  criteria	  for	  
initiating	  ARV	  treatment.	  
	  
Our	  study	  is	  a	  retrospective	  review	  of	  patients	  admitted	  to	  the	  PICU	  in	  2009,	  a	  period	  when	  
there	  was	  very	  little	  published	  data	  on	  initiating	  ARV	  therapy.	  There	  is	  now	  clear	  evidence	  
that	  starting	  ARV	  therapy	  in	  early	  infancy	  improves	  survival.	  However,	  there	  is	  very	  little	  
data	  on	  initiating	  ARV	  therapy	  in	  critically	  ill	  children	  during	  a	  PICU	  admission.	  	  
	  
Immune	  reconstitution	  inflammatory	  syndrome	  (IRIS):	  
The	  immune	  reconstitution	  inflammatory	  syndrome	  refers	  to	  the	  paradoxical	  deterioration	  
in	  clinical	  status	  of	  some	  patients,	  following	  initiation	  of	  antiretroviral	  therapy,	  with	  
suppression	  of	  the	  HIV	  viral	  load	  and	  increasing	  CD4	  counts.	  	  
	  
Smith	  et	  al	  (6)	  prospectively	  reported	  the	  incidence,	  clinical	  manifestation	  and	  risk	  factors	  
in	  a	  cohort	  of	  HIV	  infected	  children	  initiating	  ARV	  therapy	  between	  April	  2005	  and	  
November	  2006.	  They	  report	  that	  21%	  (34/162)	  of	  HIV	  infected	  children	  developed	  IRIS	  at	  
a	  median	  of	  16	  days	  (range	  7	  –	  115	  days)	  post	  ARV	  initiation.	  BCG	  adenitis	  occurred	  in	  71%	  
(24/34)	  of	  children,	  12	  children	  were	  diagnosed	  with	  Tuberculosis,	  whilst	  single	  cases	  of	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CMV	  pneumonia,	  streptococcus	  pneumonia	  and	  severe	  seborrheic	  dermatitis	  were	  
described.	  IRIS	  occurred	  more	  frequently	  in	  younger	  children	  with	  severe	  
immunosuppression,	  median	  CD4	  count	  13.9.	  
	  
Puthanakit	  et	  al	  (7)	  prospectively	  reported	  the	  incidence	  and	  spectrum	  of	  IRIS	  in	  a	  cohort	  of	  
severely	  immunosuppressed	  HIV	  infected	  children	  in	  Thailand,	  commencing	  ARV	  therapy	  
between	  May	  2002	  and	  November	  2004.	  They	  enrolled	  153	  children	  and	  described	  the	  
incidence	  of	  IRIS	  to	  be	  19%	  (32/153),	  which	  occurred	  at	  a	  median	  of	  4	  weeks	  (range	  2	  –	  31	  
weeks),	  after	  initiating	  ARV	  therapy.	  Mycobacterial	  organisms	  caused	  14	  episodes	  of	  IRIS,	  
varicella	  zoster	  virus	  and	  herpes	  simplex	  virus	  were	  each	  implicated	  in	  7	  episodes,	  there	  
were	  3	  episodes	  of	  Cryptococcus	  neoformans	  and	  1	  episode	  of	  Guillan-­‐Barre’	  syndrome.	  Two	  
children	  with	  IRIS	  were	  treated	  with	  short	  courses	  of	  steroids	  and	  3	  children	  died	  from	  
complications	  of	  IRIS.	  They	  also	  found	  that	  the	  children	  who	  developed	  IRIS	  had	  lower	  
baseline	  CD4	  counts,	  compared	  to	  the	  children	  who	  did	  not	  develop	  IRIS.	  	  
	  
Rabie	  et	  al	  (8)	  prospectively	  reported	  the	  incidence	  of	  BCG-­‐IRIS	  (regional	  adenitis)	  in	  
relation	  to	  children	  randomized	  to	  either	  early	  or	  deferred	  ARV	  initiation	  in	  the	  CHER	  study	  
(3).	  Early	  treatment	  referred	  to	  children	  who	  commenced	  ARV	  treatment	  before	  12	  weeks	  
of	  age	  and	  who	  had	  CD4	  counts	  greater	  than	  25%.	  Deferred	  treatment	  referred	  to	  infants	  
who	  only	  commenced	  ARV	  treatment	  once	  their	  CD4	  counts	  dropped	  below	  25%,	  or	  
developed	  CDC	  stage	  C	  or	  severe	  stage	  B	  disease.	  They	  included	  369	  infants,	  reporting	  that	  
28	  infants	  developed	  BCG	  IRIS	  within	  2	  months	  and	  32	  (8.7%)	  children	  developed	  BCG	  IRIS	  
within	  6	  months	  of	  commencing	  ARV	  treatment.	  They	  reported	  that	  the	  incidence	  of	  BCG	  
IRIS	  in	  children	  who	  commenced	  early	  ARV’s	  was	  10.9	  per	  100	  person-­‐years,	  compared	  to	  
54.3	  per	  100	  person-­‐years	  in	  children	  with	  deferred	  ARV	  treatment.	  They	  also	  reported	  that	  
low	  CD4	  counts	  and	  high	  HIV	  viral	  loads	  were	  associated	  with	  an	  increased	  risk	  of	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developing	  IRIS.	  They	  concluded	  that	  initiating	  ARV	  therapy	  before	  children	  deteriorated	  
immunologically	  or	  clinically,	  reduced	  the	  risk	  of	  BCG	  IRIS.	  
	  
Walters	  et	  al	  (9)	  retrospectively	  reviewed	  the	  records	  of	  HIV	  infected	  children	  initiating	  
ARV	  therapy	  between	  January	  2003	  and	  December	  2005.	  They	  included	  290	  children	  and	  
described	  Tuberculosis	  in	  48%	  (136/290)	  of	  the	  children.	  One	  hundred	  and	  sixteen	  of	  the	  
Tuberculosis	  episodes	  occurred	  before	  initiation	  of	  ARV’s,	  and	  10	  of	  the	  21	  episodes	  that	  
occurred	  after	  initiating	  ARV’s	  were	  considered	  to	  be	  related	  to	  IRIS.	  They	  postulated	  that	  
early	  initiation	  of	  ARV	  therapy	  would	  most	  likely	  reduce	  Tuberculosis	  related	  morbidity	  
and	  mortality	  in	  Tuberculosis	  endemic	  areas.	  	  
	  
A	  systematic	  literature	  review	  (10)	  reported	  on	  Tuberculosis	  associated	  IRIS	  (TB-­‐IRIS)	  in	  
children	  commencing	  ARV	  therapy.	  They	  included	  13	  studies	  of	  which	  6	  were	  retrospective,	  
2	  prospective,	  1	  cross-­‐sectional,	  3	  case	  reports	  and	  1	  case	  series.	  They	  described	  303	  cases	  
of	  TB-­‐IRIS,	  with	  the	  median	  time	  from	  ARV	  initiation	  to	  IRIS	  diagnosis	  ranging	  from	  8	  days	  
to	  16	  weeks.	  Treatment	  was	  only	  described	  in	  2	  cases,	  and	  both	  received	  steroids.	  Few	  
deaths	  were	  described,	  and	  it	  was	  difficult	  attributing	  the	  cause	  of	  death	  to	  the	  underlying	  
disease	  or	  a	  complication	  of	  IRIS.	  They	  concluded	  that	  there	  was	  limited	  information	  on	  TB-­‐
IRIS,	  with	  research	  needed	  to	  assess	  the	  risk	  factors,	  incidence	  and	  optimum	  treatment.	  
	  
IRIS	  is	  a	  recognized	  complication	  following	  initiation	  of	  ARV	  therapy.	  The	  available	  
paediatric	  data	  on	  the	  risk	  factors,	  treatment	  and	  outcome	  of	  children	  with	  IRIS	  is	  limited.	  	  
The	  majority	  of	  children	  described	  to	  have	  developed	  IRIS	  were	  from	  outpatient	  settings	  
and	  not	  from	  initiating	  ARV	  therapy	  in	  intensive	  care.	  Severe	  immunosuppression	  is	  a	  well	  
described	  risk	  factor	  for	  developing	  IRIS,	  which	  means	  that	  children	  initiating	  ARV	  therapy	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whilst	  critically	  ill,	  may	  have	  a	  higher	  incidence	  of	  IRIS.	  Only	  1	  study	  reported	  the	  use	  of	  
steroid	  treatment	  for	  IRIS	  and	  the	  mortality	  associated	  with	  IRIS	  appears	  to	  be	  low.	  	  
With	  the	  high	  incidence	  of	  Tuberculosis	  in	  South	  Africa,	  BCG	  adenitis	  and	  pulmonary	  
tuberculosis	  is	  a	  particular	  concern	  after	  initiating	  ARV	  therapy	  in	  HIV	  infected	  children.	  	  
	  
	  
The	  prevalence	  of	  CMV	  infection	  in	  HIV	  infected	  children	  
HIV	  infected	  children	  are	  at	  high	  risk	  of	  opportunistic	  infections.	  PCP	  was	  commonly	  
described	  in	  HIV	  infected	  children	  and	  has	  been	  associated	  with	  high	  mortality(11).	  
However,	  CMV	  infection	  has	  gradually	  also	  been	  recognized	  as	  being	  a	  major	  pathogen	  
causing	  lung	  disease	  and	  death	  in	  immunosuppressed	  HIV	  infected	  children.	  
	  
Ikeogu	  et	  al	  (12)	  reported	  the	  autopsy	  findings	  of	  a	  group	  of	  Zimbabwean	  children,	  under	  5	  
years	  of	  age,	  who	  died	  at	  home	  or	  shortly	  after	  hospital	  admission.	  The	  aim	  of	  the	  study	  was	  
to	  describe	  the	  spectrum	  of	  lung	  disease	  in	  HIV	  infected	  children	  from	  a	  developing	  country.	  	  
Over	  a	  10	  month	  period	  between	  July	  1992	  and	  April	  1993,	  they	  reported	  HIV	  infection	  in	  
66%	  (122/184)	  of	  these	  children,	  positive	  bacterial	  cultures	  in	  86%	  (106/122)	  of	  children,	  
Tuberculosis	  in	  5%	  of	  children	  (6/122),	  19%	  of	  the	  HIV	  infected	  children	  had	  PCP	  and	  7%	  
had	  evidence	  of	  CMV	  infection.	  	  
	  
Chintu	  et	  al	  (13)	  performed	  autopsies	  in	  order	  to	  determine	  the	  cause	  of	  death	  in	  a	  group	  of	  
hospitalized	  Zambian	  children,	  who	  died	  from	  respiratory	  illness.	  This	  descriptive	  study	  
was	  performed	  between	  June	  1997	  and	  September	  2000,	  and	  included	  180	  HIV	  infected	  
children	  and	  84	  HIV	  negative	  children.	  The	  commonest	  cause	  of	  death	  in	  both	  groups	  of	  
children	  was	  acute	  pyogenic	  pneumonia.	  In	  the	  group	  of	  HIV	  infected	  children,	  PCP	  was	  
identified	  in	  29%,	  CMV	  in	  22%	  and	  tuberculosis	  in	  18%	  of	  the	  cases.	  They	  reported	  that	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only	  3	  of	  the	  40	  children	  had	  evidence	  of	  necrotizing	  CMV	  pneumonia,	  suggested	  that	  the	  
majority	  of	  children	  had	  mild	  CMV	  infections	  and	  that	  treatment	  with	  Gancyclovir	  was	  toxic	  
and	  too	  expensive	  for	  most	  African	  countries.	  
	  
Goussard	  et	  al	  (14)	  prospectively	  described	  the	  role	  of	  CMV	  co-­‐infection	  in	  ventilated	  HIV	  
infected	  children	  with	  possible	  PCP,	  using	  the	  pp65	  test	  for	  CMV	  antigen	  and	  lung	  biopsies.	  
Twenty-­‐five	  children	  were	  recruited	  between	  April	  2001	  and	  April	  2005,	  with	  17	  of	  them	  
having	  lung	  biopsies	  and	  8	  children	  had	  post	  mortem	  lung	  tissue	  biopsies.	  They	  diagnosed	  
CMV	  pneumonia	  in	  72%	  of	  the	  children.	  Thirty-­‐six	  percent	  of	  children	  were	  infected	  with	  
both	  CMV	  and	  PCP,	  whilst	  24	  %	  of	  children	  had	  only	  PCP	  isolated.	  The	  pp65	  antigen	  test	  for	  
CMV	  had	  a	  false	  negative	  rate	  of	  24%.	  All	  of	  the	  children	  were	  treated	  for	  PCP	  and	  only	  1	  of	  
these	  children	  were	  treated	  with	  gancyclovir.	  The	  PICU	  mortality	  rate	  in	  this	  study	  was	  72%	  
and	  overall	  hospital	  mortality	  rate	  in	  this	  group	  of	  children	  was	  88%.	  
	  
Kitchen	  et	  al	  (15)	  prospectively	  studied	  a	  group	  of	  HIV	  infected	  and	  exposed	  children	  
admitted	  to	  their	  PICU	  with	  respiratory	  failure.	  They	  recruited	  63	  children,	  of	  which	  53	  
were	  HIV	  infected	  and	  10	  were	  HIV	  exposed	  but	  not	  infected.	  All	  children	  were	  empirically	  
treated	  with	  broad-­‐spectrum	  antibiotics,	  cotrimoxazole/prednisone	  for	  suspected	  PCP	  and	  
with	  Gancyclovir	  for	  suspected	  CMV	  infection.	  PCP	  was	  diagnosed	  in	  33%	  of	  these	  infants	  
and	  38%	  of	  these	  children	  had	  a	  CMV	  viral	  load	  greater	  than	  log	  4.0	  copies/ml.	  	  
They	  reported	  that	  32%	  of	  HIV	  infected	  children	  and	  20%	  of	  HIV	  uninfected	  children	  died	  
in	  this	  study,	  with	  the	  risk	  of	  death	  significantly	  higher	  in	  children	  with	  CMV	  disease.	  	  
	  
Zampoli	  et	  al	  (16)	  prospectively	  	  investigated	  the	  prevalence	  and	  outcomes	  	  CMV	  associated	  
pneumonia	  in	  hospitalized	  children	  from	  December	  2006	  to	  June	  2008.	  They	  considered	  
children	  to	  have	  active	  CMV	  infection	  if	  either	  blood	  or	  respiratory	  tract	  secretions	  had	  a	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CMV	  viral	  load	  greater	  than	  or	  equal	  to	  log	  4.0	  copies/ml.	  The	  study	  recruited	  124	  HIV	  
infected	  children	  and	  76	  HIV	  uninfected	  children.	  They	  diagnosed	  PCP	  in	  27%	  of	  the	  
children,	  CMV	  associated	  pneumonia	  in	  28%	  of	  the	  children,	  with	  a	  prevalence	  of	  36%	  in	  
HIV	  infected	  children	  and	  15%	  in	  HIV	  negative	  children.	  HIV	  infected	  children	  had	  a	  
reported	  mortality	  of	  35%	  compared	  to	  11%	  in	  HIV	  uninfected	  children.	  Gancyclovir	  use	  
was	  not	  consistent,	  with	  68%	  (25/37)	  of	  HIV	  infected	  children	  and	  80%	  (8/10)	  HIV	  
uninfected	  children	  with	  CMV	  associated	  pneumonia	  receiving	  gancyclovir.	  They	  reported	  a	  
mortality	  of	  43%	  (9/21	  children)	  in	  HIV	  infected	  children	  with	  CMV	  associated	  pneumonia	  
treated	  with	  Gancyclovir,	  compared	  to	  88%	  (7/8	  children)	  in	  children	  not	  treated	  with	  
Gancyclovir.	  The	  authors	  concluded	  that	  empiric	  Gancyclovir	  may	  be	  indicated	  in	  immune-­‐
suppressed,	  HIV	  infected	  children	  presenting	  with	  pneumonia.	  
	  	  
Hsiao	  et	  al	  (17)	  performed	  a	  cross-­‐sectional	  study,	  comparing	  the	  prevalence	  and	  level	  of	  
CMV	  viraemia	  in	  asymptomatic	  HIV	  exposed	  infants	  and	  symptomatic	  HIV	  exposed	  infants	  
hospitalized	  with	  suspected	  PCP	  between	  December	  2006	  and	  June	  2008.	  They	  included	  
283	  asymptomatic	  HIV	  exposed	  infants	  and	  142	  HIV	  exposed	  infants	  with	  severe	  
pneumonia.	  They	  found	  that	  68%	  of	  symptomatic	  HIV	  exposed	  infants	  with	  pneumonia	  had	  
a	  high	  CMV	  viral	  load	  compared	  to	  only	  24%	  of	  asymptomatic	  HIV	  exposed	  infants	  and	  that	  
prevalence	  and	  level	  of	  CMV	  viraemia	  peaked	  at	  3-­‐4	  months	  of	  age.	  	  
	  
The	  above-­‐mentioned	  studies	  confirm	  that	  CMV	  is	  a	  common	  opportunistic	  infection	  in	  HIV	  
infected	  children.	  Performing	  a	  lung	  biopsy	  in	  order	  to	  diagnose	  CMV	  pneumonitis,	  is	  not	  
practical	  in	  critically	  ill	  ventilated	  children.	  A	  quantitative	  CMV	  viral	  load	  with	  a	  cut-­‐off	  of	  
greater	  than	  or	  equal	  to	  log	  4.0	  copies/ml	  appears	  to	  be	  a	  good	  alternative	  diagnostic	  test	  to	  
diagnose	  active	  CMV	  infection.	  However,	  whilst	  a	  positive	  CMV	  viral	  load	  might	  indicate	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active	  CMV	  disease,	  and	  likely	  CMV	  pneumonitis	  in	  a	  HIV	  infected	  children	  presenting	  with	  
pneumonia,	  it	  does	  not	  equate	  to	  a	  diagnosis	  of	  CMV	  pneumonitis.	  
	  
PICU	  and	  hospital	  survival	  rates	  
In	  2009,	  UNAIDS	  estimated	  that	  there	  were	  33.3	  million	  HIV	  infected	  people	  in	  the	  world,	  of	  
which	  22.5	  million	  people	  lived	  in	  Sub-­‐Saharan	  Africa(18).	  The	  HIV	  epidemic	  overwhelmed	  
health	  systems	  in	  Sub-­‐Saharan	  Africa,	  and	  many	  children	  died	  with	  limited	  access	  to	  
healthcare	  and	  anti-­‐retroviral	  medication(19).	  	  
	  
In	  the	  mid	  1990’s,	  before	  the	  availability	  of	  effective	  PCP	  treatment	  and	  ARV	  therapy,	  most	  
HIV	  infected	  children	  admitted	  to	  intensive	  care	  units	  in	  South	  Africa	  died.	  Mathivha	  et	  al	  
(20)	  described	  the	  outcome	  of	  HIV	  infected	  and	  HIV	  negative	  children	  requiring	  mechanical	  
ventilation	  for	  community	  acquired	  pneumonia	  in	  a	  2	  year	  period	  between	  1992	  and	  1993.	  
They	  admitted	  93	  HIV	  negative	  children	  during	  this	  period	  and	  had	  29	  deaths	  (31%).	  There	  
were	  17	  HIV	  infected	  children	  admitted	  with	  respiratory	  failure,	  of	  which	  15	  died,	  
representing	  a	  PICU	  mortality	  rate	  of	  88%.	  	  
	  
Thirsk	  et	  al	  (19)	  reported	  on	  the	  outcome	  of	  HIV	  exposed	  and	  infected	  children	  with	  
respiratory	  failure.	  They	  compared	  the	  outcomes	  of	  children	  who	  were	  offered	  mechanical	  
ventilation	  at	  a	  tertiary	  referral	  centre	  and	  with	  those	  of	  children	  who	  were	  refused	  PICU	  
admission	  from	  a	  regional	  hospital,	  with	  limited	  capacity	  to	  ventilate	  children.	  They	  
recruited	  49	  children	  in	  the	  mechanical	  ventilation	  arm	  and	  67	  children,	  who	  were	  refused	  
ventilation.	  Forty-­‐one	  percent	  of	  the	  ventilated	  children	  survived	  to	  hospital	  discharge	  
compared	  to	  24	  %	  of	  children	  who	  were	  refused	  ventilation.	  They	  concluded	  that	  in	  the	  
context	  of	  their	  small	  study,	  mechanical	  ventilation	  provided	  little	  survival	  benefit	  in	  HIV	  
infected	  children	  admitted	  with	  acute	  respiratory	  failure.	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Rabie	  et	  al	  (21)	  retrospectively	  described	  the	  outcomes	  of	  HIV	  infected	  children	  admitted	  to	  
their	  PICU	  over	  a	  1	  year	  period	  in	  2003,	  prior	  to	  the	  availability	  of	  ARV	  treatment.	  They	  had	  
47	  HIV	  infected	  admissions	  with	  17	  children	  (36%)	  dying	  in	  PICU,	  and	  another	  4	  children	  
died	  shortly	  after	  PICU	  discharge.,	  for	  an	  overall	  hospital	  mortality	  rate	  of	  nearly	  50%.	  
	  	  	  	  	  
Cooper	  et	  al	  (22)	  retrospectively	  reported	  the	  10	  year	  experience	  of	  HIV	  infected	  children	  
admitted	  to	  a	  PICU	  in	  the	  United	  Kingdom	  between	  1992	  and	  2002.	  During	  this	  period,	  42	  
HIV	  infected	  children	  had	  66	  admission	  episodes.	  Sixteen	  (38%)	  children	  died	  in	  PICU,	  5	  
children	  died	  after	  PICU	  discharge	  and	  21	  (50%)	  children	  were	  alive	  at	  the	  time	  of	  
reporting.	  Seventy-­‐seven	  percent	  of	  the	  children	  were	  admitted	  for	  respiratory	  failure	  and	  
11%	  had	  elective	  admissions	  following	  surgery.	  They	  reported	  good	  growth	  and	  
development	  outcomes	  in	  80%	  of	  surviving	  children.	  
	  
In	  developed	  countries,	  ARV	  therapy	  was	  introduced	  in	  the	  mid	  1990’s	  for	  HIV	  infected	  
children.	  de	  Martino	  et	  al	  (23)	  conducted	  a	  multi-­‐centered,	  population	  based,	  longitudinal	  
study	  of	  HIV	  infected	  children	  in	  the	  Italian	  registry.	  They	  included	  1142	  HIV	  infected	  
children	  born	  between	  1980	  and	  1997,	  specifically	  reporting	  on	  the	  time	  to	  death	  of	  birth	  
cohorts	  and	  related	  them	  to	  the	  administered	  ARV	  therapy.	  They	  found	  improved	  survival	  
in	  HIV	  infected	  children	  in	  1996	  –	  1998,	  concluding	  that	  it	  was	  related	  to	  combined	  ARV	  
therapy.	  Similarly,	  Resino	  et	  al	  (24)	  reported	  on	  the	  effect	  of	  ARV	  therapy	  on	  the	  outcomes	  
of	  427	  HIV	  infected	  Spanish	  children	  	  from	  1980	  until	  2003.	  
From	  1980	  to	  1989	  ARV	  therapy	  was	  not	  available,	  monotherapy	  was	  used	  between	  1990	  
and	  1993,	  combined	  therapy	  was	  introduced	  between	  1994	  and	  1996,	  with	  increasing	  
numbers	  of	  children	  established	  on	  ARV	  therapy	  over	  the	  following	  years.	  They	  concluded	  
	  
	   xix	  
that	  effective	  ARV	  therapy	  for	  HIV	  children	  reduced	  the	  number	  of	  hospital	  admissions,	  
reduced	  disease	  progression	  and	  death.	  
	  
The	  intensive	  care	  and	  hospital	  outcomes	  of	  HIV	  infected	  children	  have	  historically	  been	  
affected	  by	  access	  to	  appropriate	  treatment	  as	  well	  as	  treatment	  limitations	  based	  on	  their	  
severity	  of	  illness	  and	  poor	  long	  term	  prognosis.	  What	  has	  become	  clear	  is	  that	  HIV	  infected	  
children	  who	  do	  not	  start	  ARV	  therapy,	  have	  a	  high	  mortality	  rate.	  With	  the	  availability	  of	  
effective	  ARV	  treatment	  programmes,	  paediatric	  intensive	  care	  and	  hospital	  survival	  rates	  
of	  critically	  ill	  HIV	  infected	  children	  have	  steadily	  improved	  over	  the	  past	  2	  decades.	  Thus,	  
HIV	  infection	  per	  se,	  should	  not	  be	  an	  exclusion	  criterion	  for	  admission	  to	  intensive	  care	  
units	  in	  developing	  countries.	  	  
	  
c) Needs	  for	  further	  research	  
i)	  An	  effective	  PMTCT	  programme	  currently	  offers	  the	  only	  hope	  of	  preventing	  HIV	  disease	  
in	  children.	  Early	  initiation	  of	  ARV	  medication	  has	  clearly	  been	  associated	  with	  increased	  
survival.	  There	  is	  an	  ongoing	  need	  to	  develop	  new	  ARV	  drugs	  and	  specifically	  intravenous	  
formulations.	  
	  
ii)	  There	  is	  a	  need	  to	  develop	  more	  reliable	  tests	  to	  diagnose	  PCP	  and	  CMV,	  which	  would	  
allow	  more	  directed	  treatment	  of	  critically	  ill	  HIV	  infected	  children.	  
	  
iii)	  IRIS	  is	  a	  poorly	  understood	  complication	  of	  ARV	  therapy	  and	  the	  risk	  factors	  and	  optimal	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Objectives:	  The	  aim	  of	  the	  study	  was	  to	  report	  the	  1-­‐year	  experience	  of	  initiating	  ARV’s	  and	  the	  
empiric	  use	  of	  gancyclovir	  therapy	  in	  HIV	  infected	  children	  admitted	  to	  our	  PICU.	  
	  
Design:	  	  Retrospective	  cohort	  study	  
Setting:	  	  PICU,	  Red	  Cross	  War	  Memorial	  Children’s	  Hospital,	  Cape	  Town,	  South	  Africa	  
Patients:	  	  All	  HIV	  infected	  and	  HIV	  exposed	  children	  admitted	  to	  the	  PICU	  in	  2009	  
Intervention:	  	  None	  	  
Measurements	  and	  Main	  Results:	  There	  were	  1231	  PICU	  admissions	  during	  the	  1-­‐year	  study	  
period,	  with	  144	  (11.7%)	  deaths.	  The	  standardized	  mortality	  ratio	  (PIM2)	  was	  0.74.	  There	  
were	  123	  HIV	  related	  admissions;	  75	  HIV	  infected	  children	  had	  85	  admissions,	  there	  were	  24	  
HIV	  exposed	  but	  HIV	  negative	  admissions	  and	  14	  HIV	  exposed	  children	  had	  no	  confirmatory	  
tests.	  Respiratory	  failure	  was	  the	  main	  reason	  for	  PICU	  admission	  in	  68%	  of	  cases.	  Only	  29%	  of	  
HIV	  infected	  children	  were	  known	  to	  have	  received	  PMTCT.	  HIV	  infected	  children	  had	  a	  median	  
age	  of	  4	  months	  (IQR	  3-­‐7),	  were	  admitted	  for	  a	  median	  of	  6	  days	  (IQR	  3-­‐12)	  and	  spent	  a	  median	  
of	  16	  days	  (IQR	  9-­‐28)	  in	  hospital	  after	  PICU	  discharge.	  On	  admission,	  24	  children	  were	  on	  
ARV’s	  and	  31	  children	  commenced	  ARV’s	  on	  PICU.	  	  The	  PCP	  immunofluorescence	  test	  was	  
positive	  in	  25%	  of	  children	  not	  on	  ARV’s.	  Thirty-­‐eight	  percent	  of	  children	  admitted	  on	  ARV’s	  
had	  a	  positive	  CMV	  viral	  load,	  and	  57%	  of	  the	  HIV	  infected	  children	  not	  on	  ARV’s	  on	  admission	  
had	  a	  positive	  CMV	  viral	  load.	  Fourteen	  (29%)	  children	  who	  started	  ARV’s	  during	  the	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admission	  developed	  IRIS.	  Seventy-­‐nine	  percent	  of	  HIV	  infected	  children	  survived	  to	  PICU	  
discharge	  and	  69%	  of	  children	  survived	  to	  hospital	  discharge.	  Thirty-­‐one	  HIV	  infected	  children,	  
61%	  of	  the	  children	  discharged	  home,	  were	  known	  to	  be	  alive	  1	  year	  later.	  
Conclusions:	  	  The	  numbers	  of	  HIV	  infected	  children	  surviving	  PICU	  and	  hospital	  admissions	  
have	  increased.	  Antiretroviral	  therapy	  was	  successfully	  initiated	  in	  PICU	  and	  apart	  from	  the	  
risk	  of	  IRIS,	  there	  were	  no	  obvious	  side	  effects	  to	  commencing	  ARV’s	  in	  critically	  ill	  children.	  
CMV	  is	  a	  common	  opportunistic	  infection	  in	  HIV	  infected	  children	  and	  empiric	  therapy	  with	  
Gancyclovir	  should	  be	  considered	  whilst	  confirmatory	  blood	  results	  are	  awaited.	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INTRODUCTION	  
The	  survival	  of	  critically	  ill,	  HIV	  infected	  children	  in	  South	  Africa	  has	  changed	  dramatically	  over	  
the	  past	  20	  years.	  	  During	  the	  mid	  to	  late	  1990’s,	  nearly	  all	  HIV	  infected	  children	  admitted	  to	  
paediatric	  intensive	  care	  units	  (PICU’s)	  in	  South	  Africa	  died	  (1,2).	  There	  were	  also	  reports	  that	  
the	  mortality	  of	  HIV	  infected	  children	  was	  similar	  with	  and	  without	  the	  availability	  of	  
paediatric	  intensive	  care	  treatment	  (3).	  This	  was	  in	  the	  context	  of	  an	  increasing	  HIV	  epidemic	  
(4-­‐6),	  a	  limited	  number	  of	  PICU	  beds	  in	  state	  hospitals	  (7)	  and	  the	  South	  African	  government	  
refusing	  to	  supply	  anti-­‐	  retroviral	  (ARV)	  medication	  to	  public	  sector	  patients	  (4,8).	  This	  
resulted	  in	  most	  intensive	  care	  units	  refusing	  admission	  to	  HIV	  infected	  children	  with	  life-­‐
threatening	  illnesses.	  
The	  reality	  was	  that	  HIV	  infected	  children	  without	  access	  to	  ARV	  therapy	  were	  doomed	  to	  die.	  
Hussey	  et	  al	  (9)	  demonstrated	  that	  the	  median	  survival	  in	  193	  newly	  diagnosed	  HIV	  infected	  
children	  was	  32	  months	  from	  the	  time	  of	  diagnosis.	  The	  lack	  of	  ARV	  medication	  resulted	  in	  an	  
increase	  in	  the	  number	  of	  children	  dying	  in	  hospitals	  (6)	  and	  an	  increase	  in	  the	  national	  under	  
5	  childhood	  mortality	  rates	  (10).	  
From	  the	  early	  2000’s,	  with	  an	  increased	  understanding	  of	  disease	  processes,	  and	  the	  
availability	  of	  private	  donor	  funded	  ARV’s	  South	  African	  PICU’s	  subsequently	  reported	  survival	  
rates	  of	  HIV	  infected	  children	  at	  about	  75%,	  with	  approximately	  50%	  of	  children	  surviving	  to	  
hospital	  discharge	  (11,12)(Salie	  unpublished	  data).	  This	  was	  not	  too	  dissimilar	  to	  the	  survival	  
of	  HIV	  infected	  children	  admitted	  to	  resource	  rich	  intensive	  care	  units	  in	  developed	  
countries(13).	  	  
This	  improved	  survival	  could	  be	  attributed	  to	  a	  number	  of	  factors	  including;	  effective	  treatment	  
of	  Pneumocystis	  jirovecci	  Pneumonia	  (PCP),	  improvements	  in	  ventilator	  management	  strategies	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(14)	  and	  technology	  available	  to	  treat	  critically	  ill	  children	  with	  septic	  shock	  and	  acute	  
respiratory	  distress	  syndrome	  (15).	  
The	  South	  African	  government	  made	  ARV	  drugs	  available	  to	  public	  sector	  patients	  in	  November	  
2003	  (16).	  	  There	  have	  been	  several	  approaches	  to	  commencing	  ARV	  medication,	  but	  the	  
optimal	  time	  for	  initiating	  ARV’s	  in	  critically	  ill	  children	  in	  PICU	  has	  not	  been	  determined.	  	  
	  
Recent	  research	  has	  clearly	  shown	  improved	  survival	  from	  early	  initiation	  of	  ARV’s	  (17).	  The	  
CHER	  study	  group	  (18)	  was	  able	  to	  demonstrate	  a	  76%	  reduction	  in	  early	  infant	  mortality	  and	  
75%	  reduction	  in	  HIV	  progression	  by	  diagnosing	  HIV	  early	  and	  commencing	  ARV’s	  
immediately.	  	  
The	  majority	  of	  children	  currently	  commence	  ARV’s	  from	  outpatient	  clinics	  or	  hospital	  wards.	  
There	  is	  very	  little	  data	  on	  the	  initiation	  of	  ARV’s	  in	  critically	  ill	  children	  in	  intensive	  care	  units.	  
The	  hesitancy	  in	  initiating	  ARV’s	  in	  critically	  ill	  children	  was	  related	  to	  the	  fact,	  that	  ARVS’s	  
were	  thought	  not	  to	  improve	  the	  child’s	  condition	  in	  the	  short	  term	  and	  there	  was	  the	  potential	  
for	  drug	  toxicity	  (19),	  particularly	  in	  critically	  ill	  children.	  An	  additional	  concern	  about	  starting	  
ARV’s	  in	  acutely	  ill	  children	  has	  been	  the	  potential	  for	  developing	  immune	  reconstitution	  
inflammatory	  syndrome	  (IRIS)	  (20,21),	  with	  associated	  deterioration	  in	  clinical	  condition.	  
	  
Respiratory	  failure	  is	  probably	  the	  commonest	  reason	  for	  PICU	  admission	  in	  HIV	  infected	  
children	  (11,13,22).	  HIV	  infected	  children	  are	  not	  only	  susceptible	  to	  the	  usual	  viral	  and	  
bacterial	  pathogens,	  but	  are	  also	  at	  increased	  risk	  of	  opportunistic	  infections	  (23).	  PCP	  has	  
been	  the	  commonest	  described	  opportunistic	  infection,	  but	  Cytomegalovirus	  (CMV)	  infection	  
has	  increasingly	  been	  recognized	  as	  a	  common	  co-­‐infection	  in	  HIV	  infected	  children	  (22,24-­‐26).	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In	  developing	  countries,	  with	  a	  high	  Tuberculosis	  prevalence,	  HIV	  infected	  children	  are	  also	  at	  
increased	  risk	  of	  Pulmonary	  Tuberculosis	  (27).	  
Diagnosing	  CMV	  infection	  in	  resource-­‐limited	  settings	  is	  challenging,	  with	  confirmatory	  tests	  
often	  only	  available	  several	  days	  after	  admission.	  Treatment	  for	  CMV	  is	  also	  problematic	  as	  
gancyclovir	  is	  not	  widely	  available.	  
	  
Since	  2008,	  our	  PICU	  and	  infectious	  diseases	  teams	  changed	  the	  management	  approach	  to	  
critically	  ill	  HIV	  infected	  children.	  ARV	  medication	  was	  started	  in	  PICU	  as	  soon	  as	  the	  diagnosis	  
of	  HIV	  infection	  was	  confirmed	  and	  the	  child’s	  caregivers	  had	  been	  counseled.	  In	  addition,	  
gancyclovir	  was	  started	  empirically	  on	  admission,	  in	  all	  HIV	  infected	  children	  with	  severe	  
pneumonia	  and	  sepsis.	  
	  
The	  aim	  of	  this	  retrospective	  study	  was	  to	  review	  the	  outcome	  of	  HIV	  infected	  children	  
admitted	  to	  our	  PICU	  during	  2009,	  who	  had	  ARV’s	  initiated	  as	  soon	  as	  the	  diagnosis	  was	  
confirmed	  and	  who	  were	  empirically	  treated	  with	  Gancyclovir	  for	  suspected	  CMV	  infection.	  
	  
MATERIALS	  AND	  METHODS	  
Setting	  	  
The	  study	  was	  conducted	  in	  the	  PICU	  of	  the	  Red	  Cross	  War	  Memorial	  Children’s	  Hospital,	  
situated	  in	  Cape	  Town,	  South	  Africa.	  It	  is	  a	  20	  bed,	  multidisciplinary	  unit	  with	  approximately	  
1250	  admissions	  per	  year.	  Approximately	  60%	  of	  admissions	  are	  for	  acute	  emergencies	  and	  
about	  70%	  of	  admissions	  require	  ventilatory	  support.	  This	  is	  the	  largest	  PICU	  in	  South	  Africa	  
and	  a	  team	  of	  paediatric	  intensivists,	  rotating	  registrars	  and	  nursing	  staff,	  delivers	  patient	  care.	  
The	  expertise	  of	  the	  PICU	  team	  is	  broadened	  by	  the	  availability	  of	  an	  interested	  infectious	  
diseases	  department,	  supported	  by	  reliable	  microbiology	  and	  virology	  laboratories.	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Design	  and	  Patients	  
Approval	  for	  the	  study	  was	  obtained	  from	  the	  Human	  Research	  Ethics	  Committee	  of	  the	  
University	  of	  Cape	  Town	  and	  the	  Red	  Cross	  War	  Memorial	  Children’s	  Hospital	  research	  review	  
committee.	  	  
	  
We	  conducted	  a	  retrospective	  cohort	  study	  of	  all	  HIV	  exposed	  and	  infected	  children	  admitted	  to	  
the	  PICU	  during	  2009.	  These	  children	  were	  identified	  from	  the	  intensive	  care	  unit’s	  patient	  
database.	  Data	  was	  collected	  from	  the	  intensive	  care	  unit	  database,	  patient	  folders,	  the	  hospital	  
laboratory	  result	  system	  and	  the	  hospital	  patient	  information	  system.	  	  
	  
All	  emergency	  and	  elective	  admissions	  to	  the	  PICU	  were	  discussed	  with	  the	  PICU	  Consultant	  on	  
call,	  who	  was	  responsible	  for	  the	  care	  of	  all	  children	  admitted	  to	  the	  intensive	  care	  unit.	  	  	  	  	  	  	  	  	  	  	  	  	  
In	  2009,	  HIV	  infection	  per	  se,	  was	  not	  an	  exclusion	  criterion	  for	  PICU	  admission.	  However,	  HIV	  
infected	  children	  with	  prolonged	  hospital	  admissions	  and	  those	  children	  who	  had	  not	  
responded	  to	  appropriate	  therapy	  were	  denied	  admission	  on	  the	  basis	  of	  having	  a	  poor	  chance	  
of	  surviving	  long	  term.	  This	  was	  done	  on	  the	  basis	  of	  a	  carefully	  considered	  hospital	  policy,	  
which	  was	  developed	  in	  consultation	  with	  clinical	  teams	  throughout	  the	  hospital	  (28).	  
	  
All	  children	  admitted	  to	  the	  PICU,	  who	  had	  not	  previously	  been	  tested	  for	  HIV,	  were	  screened	  
with	  a	  Rapid	  HIV	  test	  (Determine	  HIV	  1/2,	  Abbot	  Laboratories,	  Abbot	  Park,	  IL).	  HIV	  infection	  
was	  confirmed	  in	  HIV	  exposed	  children	  with	  an	  HIV	  polymerase	  chain	  reaction	  test	  (Amplicor	  
HIV-­‐1	  DNA	  test	  version	  1.5,	  Roche	  Diagnostics,	  GmbH,	  Mannheim,	  Germany)	  if	  they	  were	  
younger	  than	  18	  months	  and	  with	  an	  HIV	  enzyme-­‐linked	  immunosorbent	  assay	  (Architect	  HIV	  
Ag/Ab	  Combo	  ELISA,	  Abbott	  Laboratories,	  Abbott	  Park,	  IL)	  if	  they	  were	  older	  than	  18	  months	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of	  age.	  The	  infectious	  diseases	  department	  commenced	  antiretroviral	  drugs	  as	  soon	  as	  possible,	  
once	  HIV	  infection	  was	  confirmed	  and	  the	  child’s	  caregiver	  had	  received	  the	  appropriate	  
counseling	  
	  
The	  following	  investigations	  were	  routinely	  requested	  on	  children	  admitted	  with	  severe	  sepsis	  
or	  pneumonia:	  full	  blood	  count,	  serum	  electrolytes	  and	  renal	  function,	  blood	  culture,	  urinalysis,	  
tracheal	  aspirate	  (TA)	  or	  non-­‐bronchoscopic	  broncho-­‐alveolar	  lavage(BAL)	  for	  a	  respiratory	  
viral	  screen	  (multiplex	  PCR	  kit,	  Seeplex	  RV	  7	  Detection	  kit;	  Seegene,	  Rockville,	  MD),	  microscopy	  
and	  culture	  and	  PCP	  immune-­‐fluorescence	  testing	  (IF:	  Detect	  IF	  PC,	  Axis-­‐Shield,	  UK).	  	  
When	  there	  was	  a	  clinical	  concern	  about	  possible	  tuberculosis,	  a	  Mantoux	  test	  (purified	  protein	  
derivative,	  Statens	  Serum	  Institute,	  Copenhagen,	  Denmark)	  was	  done	  in	  children	  younger	  than	  
7	  years	  and	  either	  gastric	  washings	  or	  tracheal	  aspirate	  were	  sent	  for	  Mycobacterium	  
tuberculosis	  microscopy	  and	  culture.	  The	  diagnosis	  of	  Pulmonary	  Tuberculosis	  after	  initiating	  
ARV	  therapy	  was	  made	  on	  the	  basis	  of	  either	  a	  positive	  Mantoux,	  identification	  of	  acid-­‐fast	  
bacilli	  on	  microscopy	  and	  culture	  or	  clinically	  in	  children	  with	  persistent	  respiratory	  
symptoms.	  
	  
Our	  management	  strategy	  for	  children	  with	  severe	  sepsis	  or	  pneumonia	  and	  suspected	  HIV	  
infection	  included	  the	  following;	  broad-­‐spectrum	  antibiotics,	  co-­‐trimoxazole	  and	  prednisone	  
for	  suspected	  PCP,	  and	  since	  2008,	  empiric	  gancyclovir	  treatment	  for	  possible	  CMV	  infection.	  A	  
systemic	  CMV	  viral	  load	  greater	  than	  4.0	  log	  copies/ml	  was	  considered	  to	  be	  indicative	  of	  active	  
CMV	  infection	  (25,29).	  Gancyclovir	  was	  stopped	  if	  the	  systemic	  CMV	  viral	  load	  was	  less	  than	  4.0	  
log	  copies/ml.	  Children	  with	  suspected	  or	  proven	  PCP	  received	  21	  days	  therapy	  with	  
intravenous	  co-­‐trimoxazole	  and	  oral	  prednisone.	  Children	  with	  active	  CMV	  infection	  were	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treated	  for	  a	  total	  of	  42	  days	  with	  gancyclovir	  initially	  and	  changed	  to	  oral	  valgancyclovir	  when	  
they	  were	  discharged	  home.	  
	  
Non-­‐invasive	  ventilatory	  support	  was	  delivered	  with	  bubble	  nasal	  continuous	  positive	  airway	  
pressure	  (Fisher	  &	  Paykel	  Healthcare,	  Auckland,	  NZ).	  Pressure	  control	  was	  the	  main	  mode	  of	  
ventilation	  for	  mechanical	  ventilation	  and	  the	  unit	  practiced	  lung	  protective	  ventilator	  
strategies	  (30).	  High	  frequency	  oscillatory	  ventilation	  with	  the	  Sensormedics	  3100A	  
(Carefusion,	  Yorba	  Linda,	  CA),	  was	  used	  as	  a	  rescue	  mode	  of	  ventilation	  for	  children	  with	  
refractory	  hypoxaemia	  and	  hypercapnoea.	  
	  
The	  total	  daily	  fluid	  allowance	  was	  restricted	  to	  80ml/kg/day,	  including	  intravenous	  drug	  
volumes.	  Enteral	  feeds	  were	  started	  as	  soon	  as	  the	  child	  was	  haemodynamically	  stable	  and	  able	  
to	  tolerate	  feeds.	  Diuretics	  were	  used	  if	  patients	  were	  cumulatively	  fluid	  positive	  or	  developed	  
peripheral	  oedema.	  	  
	  
Data	  Analysis	  
Data	  were	  stored	  in	  a	  secure	  stata	  file	  and	  analyzed	  using	  Stata	  11	  (	  StataCorp,	  2009.	  College	  
Station,	  TX).	  The	  distribution	  of	  numerical	  variables	  was	  determined	  by	  histograms	  and	  the	  
Shapiro-­‐Wilk	  test.	  Numerical	  variables	  were	  expressed	  as	  medians	  and	  interquartile	  ranges,	  as	  
most	  did	  not	  have	  a	  normal	  distribution.	  The	  Wilcoxon	  sum	  rank	  test	  was	  used	  for	  continuous	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RESULTS	  
During	  the	  1-­‐year	  study	  period	  in	  2009,	  there	  were	  1231	  admissions	  to	  the	  PICU,	  figure	  1.	  	  	  	  	  	  	  	  
Of	  these	  admissions,	  144	  (11.7%)	  children	  died	  and	  the	  Standardized	  mortality	  ratio,	  using	  the	  
Paediatric	  Index	  of	  Mortality	  2	  (PIM2)	  (31)was	  0.74.	  	  
	  
Of	  the	  total	  number	  of	  admissions,	  123	  (10%)	  admissions	  were	  HIV	  associated.	  On	  admission,	  
44	  of	  the	  children	  were	  known	  to	  be	  HIV	  infected	  and	  79	  children	  were	  known	  to	  be	  HIV	  
exposed,	  but	  had	  not	  had	  definitive	  HIV	  testing.	  Twenty-­‐four	  HIV	  exposed	  children	  were	  found	  
to	  be	  HIV	  uninfected	  and	  14	  HIV	  exposed	  children	  had	  no	  confirmatory	  tests.	  Of	  these	  14	  
children	  with	  no	  confirmatory	  tests,	  5	  died	  and	  the	  remaining	  9	  were	  transferred	  to	  other	  
hospitals.	  Seventy-­‐five	  HIV	  infected	  children	  had	  85	  admissions.	  	  Eight	  children	  had	  2	  
admissions	  and	  1	  child	  had	  3	  admissions.	  There	  was	  no	  data	  on	  the	  number	  of	  HIV	  infected	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1231	  	  	  PICU	  admissions	   	   144	  (11.7%)	  	  PICU	  deaths	  
	  




75	  HIV	  infected	  children	  had	  85	  admissions	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  16	  (21%)	  children	  died	  in	  PICU	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  




24	  children	  HIV	  exposed	  but	  PCR	  negative	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  (13%)	  children	  died	  in	  PICU	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  (8%)	  children	  died	  in	  hospital	  wards	  
	  
	  
14	  children	  HIV	  exposed,	  had	  no	  confirmatory	  test	  
	   	   	   	   	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  children	  died	  in	  PICU	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  9	  children	  transferred	  to	  other	  hospitals	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Table	  1	  shows	  the	  PICU	  and	  hospital	  characteristics	  of	  HIV	  infected	  and	  HIV	  exposed	  children	  
admitted	  during	  the	  1-­‐year	  study	  period.	  	  The	  reasons	  for	  admission	  in	  HIV	  infected	  children	  
were	  predominantly	  for	  respiratory	  failure.	  Only	  29%	  of	  HIV	  infected	  children	  had	  documented	  
PMTCT	  compared	  to	  71%	  of	  HIV	  exposed	  but	  HIV	  negative	  children.	  Only	  22%	  of	  PCP	  
immunofluorescence	  tests	  and	  61%	  of	  CMV	  viral	  load	  tests	  performed	  on	  HIV	  infected	  children	  
were	  positive.	  	  
	  
On	  admission	  24	  HIV	  infected	  children	  were	  on	  ARV’s.	  Thirty-­‐one	  HIV	  infected	  children	  
commenced	  ARV	  treatment	  in	  PICU,	  which	  is	  61%	  of	  those	  who	  were	  eligible	  for	  treatment.	  
Two	  children	  died	  in	  PICU	  and	  1	  child	  following	  PICU	  discharge	  without	  starting	  ARV’s.	  
Seventeen	  children	  commenced	  ARV’s	  in	  the	  hospital	  ward	  prior	  to	  discharge.	  HIV	  infected	  
children	  spent	  a	  median	  of	  16	  days	  in	  the	  hospital	  wards	  before	  discharge,	  compared	  to	  a	  
median	  of	  4	  days	  in	  the	  HIV	  exposed	  children.	  Seventy	  –nine	  percent	  of	  HIV	  infected	  children	  
survived	  the	  PICU	  admission.	  Fifty-­‐two	  (69%)	  HIV	  infected	  children	  survived	  to	  hospital	  
discharge.	  Eight	  HIV	  infected	  children	  were	  referred	  for	  follow	  up	  at	  local	  hospitals	  or	  
community	  health	  clinics	  and	  no	  follow	  up	  data	  was	  available	  for	  these	  children.	  Nine	  HIV	  
infected	  children	  did	  not	  return	  for	  follow	  up	  visits.	  Four	  HIV	  infected	  children	  are	  known	  to	  
have	  died	  following	  hospital	  discharge.	  Thirty-­‐one	  HIV	  infected	  children	  were	  known	  to	  be	  
alive	  1	  year	  after	  hospital	  discharge,	  which	  represents	  60%	  of	  the	  children	  discharged	  from	  
hospital	  and	  89%	  of	  the	  children	  with	  follow	  up	  data	  1	  year	  later.	  	  There	  was	  no	  long-­‐term	  
follow	  up	  data	  for	  HIV	  exposed	  children.	  
	  
Five	  (21%)	  of	  the	  HIV	  exposed	  children	  died	  during	  the	  hospital	  admission.	  Two	  of	  these	  
children	  died	  from	  respiratory	  failure,	  1	  child	  from	  hypovolaemic/septic	  shock	  in	  PICU	  and	  2	  
children	  died	  in	  the	  hospital	  wards	  from	  complications	  of	  necrotizing	  enterocolitis	  and	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haemolytic	  uraemic	  syndrome.	  None	  of	  the	  7	  HIV	  exposed	  children	  diagnosed	  with	  pneumonia	  
had	  a	  positive	  CMV	  viral	  load.	  
	  
Table	  1:	  	  All	  HIV	  infected	  and	  exposed	  PICU	  admissions	  and	  outcome	  data	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  
HIV	  infected	  admission	  
	  	  	  (n=75	  children	  with	  85	  admissions)	  
HIV	  exposed	  admissions	  
(n=24)	  
p	  
Male	  :	  Female	   45	  :	  40	   11	  :	  13	   	  
Age	  (months)	   4	  (3	  –	  7)	   1	  (0	  –	  3)	   0.0000	  
Weight	  (kilograms)	   4.6	  (4	  –	  6.2)	   3.4	  (2.4	  –	  5.2)	   0.0019	  
PIM2	   0.23	  (0.09	  –	  0.41)	   0.09	  (0.03	  –	  0.19)	   0.008	  
Reasons	  for	  admission:	   	   	   	  
• respiratory	  failure	   58	  (68%)	   7	  (29%)	   0.0006	  
• cardiovascular	  /	  shock	   15	  (18%)	   9	  (38%)	   0.038	  
• neurological	   6	  (7%)	   0	   0.182	  
• other	   6	  (7%)	   8	  (33%)	   0.0007	  
PMTCT	   	   	   	  
• received	  PMTCT	   22	  (29%)	  children	   17	  (71%)	  children	   0.0002	  
• no	  PMTCT	   26	  (35%)	  children	   1	   0.0031	  
• unknown	   27	  (36%)	  children	   7	  (29%)	  children	   0.529	  
CD4	  count	   15.4%	  (9.4	  –	  21.4)	   -­‐	   -­‐	  
CMV	  viral	  load	  	   	   	   	  
• positive	   43	   0	   -­‐	  
• negative	   27	   7	   -­‐	  
PCP	  immunofluorescence	   	   	   	  
• positive	   14	   1	   	  
• negative	   49	   6	   -­‐	  
Anti-­‐retroviral	  drugs	   	   	   	  
• admitted	  on	  ARV’s	   	  	  	  	  	  	  	  	  	  	  	  24	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐	   -­‐	  
• started	  ARV’s	  in	  PICU	   	  	  	  	  	  	  	  	  	  	  	  31	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐	   -­‐	  
Length	  of	  ventilation	  (days)	   5	  (2	  –	  11)	   2	  (1	  –	  3.5)	   0.0002	  
Length	  of	  PICU	  stay	  (days)	   6	  (3	  –	  12)	   3	  (2	  –	  4.5)	   00005	  
Hospital	  stay	  post	  PICU	  discharge	  (days)	   16	  (9	  –	  28)	   4	  (3	  –	  8)	   0.000	  
IRIS	   	   	   	  
• BCG	  adenitis	   8	  children	   -­‐	   -­‐	  
• Pulmonary	  Tuberculosis	   6	  children	   -­‐	   -­‐	  
Discharge	  Diagnoses	   	   	   	  
• Pneumonia	   60	  (71%)	   7	  (29%)	   0.0002	  
• Septicaemia	   9	  (11%)	   5	  (21%)	   0.201	  
• Gastroenteritis	   3	   3	   00872	  
• Pneumococcal	  meningitis	   3	   -­‐	   0.352	  
• 0ther	   10	  (12%)	   8	  (33%)	   0.0147	  
Mortality	   	   	   	  
• PICU	  deaths	   16	  (21%)	  children	   3	  (13%)	   0.385	  
• Hospital	  ward	  deaths	   7	  (9%)	  children	   2	  (8%)	  children	   0.88	  
12	  month	  survival	   31	  	  children	   -­‐	   -­‐	  
	   	   	   	  
Data	  are	  presented	  as	  median	  (interquartile	  range)	  unless	  otherwise	  stated	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Table	  2	  shows	  the	  outcomes	  of	  HIV	  infected	  children	  who	  were	  admitted	  on	  ARV’s,	  those	  that	  
started	  ARV’s	  in	  PICU	  and	  following	  PICU	  discharge.	  Children	  admitted	  on	  ARV’s	  were	  older	  
than	  those	  starting	  ARV’s	  in	  PICU	  or	  the	  wards.	  None	  of	  the	  children,	  who	  were	  admitted	  on	  
ARV’s,	  were	  diagnosed	  with	  IRIS.	  Children	  who	  started	  ARV’s	  in	  PICU	  were	  ventilated	  for	  
longer,	  and	  had	  the	  longest	  PICU	  stay.	  A	  positive	  CMV	  viral	  load	  was	  found	  in	  38%	  of	  children	  
admitted	  on	  ARV’s,	  in	  58%	  of	  children	  starting	  ARV’s	  in	  PICU	  and	  in	  59%	  of	  children	  starting	  
ARV’s	  post	  PICU.	  Twenty-­‐six	  percent	  of	  children	  starting	  ARV’s	  in	  PICU	  and	  35%	  of	  children	  
starting	  ARV’s	  post	  PICU	  discharge	  developed	  IRIS.	  Fifty	  percent	  of	  children	  who	  were	  admitted	  
on	  ARV’s	  died	  and	  25%	  of	  children	  starting	  ARV’s	  in	  PICU	  died.	  	  No	  deaths	  were	  documented	  as	  
related	  to	  IRIS	  
	  
Table	  2:	  Outcomes	  of	  HIV	  infected	  children	  admitted	  on	  ARV’s,	  those	  starting	  ARV’s	  in	  
PICU	  and	  children	  starting	  ARV’s	  post	  PICU	  discharge	  
	  
	   Admitted	  on	  ARV’s	  
	  	  	  	  	  	  	  	  	  	  	  	  (n=24)	  
	  	  	  	  	  PICU	  ARV’s	  
	  	  	  	  	  	  	  	  	  	  	  	  (n=31)	  
ARV’s	  post	  PICU	  
	  	  	  	  	  	  	  	  	  (n=17)	  
	  
p	  
Age	  (months)	   13	  (5	  –	  24)	   3	  (2	  –	  4)	   3	  (2	  –	  5)	   0.00	  *	  
PIM2	   0.23	  (0.08	  –	  0.46)	   0.26	  (0.08	  –	  0.32)	   0.17	  (0.12	  –	  0.44)	   0.915	  
CD4	  count	   17	  (6	  -­‐	  26)	   12	  (8	  –	  18)	   15	  (12	  –	  21)	   0.23	  
CMV	  viral	  load	  positive	   9	   18	   10	   	  
PCP	  positive	   0	   9	   3	   	  
Length	  of	  ventilation	  (days)	   2	  (1	  –	  6)	   7	  (4	  –	  14)	   5	  (2	  –	  6)	   0.001*	  
Length	  of	  PICU	  stay	  (days)	   4	  (3	  –	  9)	   10	  (6	  –	  15)	   6(3	  –	  8)	   0.003*	  
Hospital	  stay	  post	  PICU	  discharge	  (days)	   19	  (5	  –	  30)	   17	  (9	  –	  23)	   13	  (10	  –	  21)	   0.778	  
IRIS	   	   	   	   	  
• BCG	  adenitis	   0	   5	  (16%)	   3	  (18%)	   0.85^	  
• Pulmonary	  Tuberculosis	   0	   3	  (10%)	   3	  (18%)	   0.42^	  
Mortality	   	   	   	   	  
• PICU	  deaths	   7	  (29%)	   7	  (22%)	   0	   0.55*	  
• Hospital	  ward	  deaths	   5	  (21%)	   1	  (3%)	   0	   0.033*	  
12	  month	  survival	   8	  (30%)	   13	  (43%)	   10	  (59%)	   0.332*	  
	   	   	   	   	  
Data	  are	  presented	  as	  median	  (interquartile	  range)	  unless	  otherwise	  stated	  
• Denotes	  admitted	  on	  ARV’s	  compared	  to	  PICU	  ARV’s	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The	  Discharge	  diagnoses	  and	  outcomes	  of	  HIV	  infected	  children	  are	  shown	  in	  Table	  3.	  
	  
Fifty	  HIV	  infected	  children	  had	  60	  PICU	  admissions	  for	  Pneumonia.	  A	  positive	  CMV	  viral	  load	  
was	  found	  in	  34	  (69%)	  of	  children	  and	  PCP	  in	  13	  (26%)	  of	  children	  with	  pneumonia.	  Twelve	  
(24%)	  of	  children	  diagnosed	  with	  pneumonia	  were	  infected	  with	  both	  CMV	  and	  PCP.	  There	  
were	  7	  deaths	  in	  PICU	  and	  a	  further	  5	  deaths	  in	  the	  hospital	  wards	  for	  an	  overall	  76%	  survival	  
rate	  in	  children	  diagnosed	  with	  pneumonia.	  	  
Nine	  children	  were	  diagnosed	  with	  septicaemia.	  Two	  of	  these	  children	  died	  in	  PICU,	  1	  child	  
died	  in	  the	  hospital	  ward	  for	  an	  overall	  67%	  survival	  rate	  in	  children	  diagnosed	  with	  
septicaemia.	  Of	  the	  3	  children	  diagnosed	  with	  gastroenteritis,	  1	  died	  in	  PICU,	  another	  died	  in	  
the	  hospital	  ward	  for	  an	  overall	  33%	  survival	  rate.	  All	  3	  children	  diagnosed	  with	  pneumococcal	  
meningitis	  died	  in	  PICU.	  Both	  children	  diagnosed	  with	  CMV	  enteritis	  died	  in	  PICU.	  The	  
remaining	  children	  had	  a	  variety	  of	  discharge	  diagnoses	  including;	  myocarditis,	  poisoning,	  
elective	  surgical	  admissions	  following	  patent	  ductus	  arterious	  closures,	  ventricular	  septal	  
defect	  repairs	  and	  laryngeal	  cleft	  surgery	  
	  
Table	  3:	  Discharge	  diagnoses	  and	  outcomes	  of	  HIV	  infected	  children	  
	  
Diagnosis	   PICU	  mortality	   Ward	  mortality	   Survivors	  
Pneumonia	  	  (n=50)	   7	   5	   38	  (76%)	  
Septicaemia	  	  (n=9)	   2	   1	   6	  (67%)	  
Gastroenteritis	  	  (n=3)	   1	   1	   1	  (33%)	  
Pneumococcal	  Meningitis	  (n=3)	   3	   -­‐	   0	  
CMV	  enteritis	  	  (n=2)	   2	   -­‐	   0	  
	  
Table	  4	  shows	  the	  characteristics	  of	  the	  16	  HIV	  infected	  children	  who	  died	  in	  PICU.	  The	  3	  
children	  diagnosed	  with	  meningococcal	  meningitis	  died	  within	  2	  days	  of	  admission.	  Only	  2	  of	  
the	  children	  who	  died	  were	  not	  on	  ARV	  drugs.	  Seven	  children	  who	  had	  ARV’s	  commenced	  in	  
PICU	  died	  during	  the	  admission	  episode.	  The	  2	  children	  diagnosed	  with	  CMV	  enteritis	  both	  died	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and	  CMV	  was	  identified	  in	  another	  2	  children	  who	  died	  from	  pneumonia.	  Ten	  of	  these	  children	  
had	  treatment	  withdrawn,	  as	  a	  result	  of	  not	  responding	  to	  appropriate	  care.	  
	  
Table	  4:	  HIV	  infected	  children	  dying	  in	  PICU	  
	  	  
PICU	  






started	   Diagnosis	  /	  Cause	  of	  Death	  
	  	  	  1.	  	   26	   0.93	   1	   Previously	   Pneumococal	  meningitis	  
	  	  	  2.	   24	   0.23	   2	   Previously	   MRSA	  sepsis,	  pneumonia	  
	  	  	  3.	   10	   0.66	   5	   Previously	   Gut	  necrosis,	  Klebsiella/E.	  coli	  sepsis	  
	  	  	  4.	   3	   0.58	   7	   No	   CMV	  enteritis,	  Klebsiella	  sepsis	  
	  	  	  5.	   4	   0.59	   7	   Previously	   CMV	  enteritis,	  E.	  Coli	  sepsis	  
	  	  	  6.	   4	   0.61	   5	   PICU	   Pneumonia,	  E.coli	  sepsis	  
	  	  	  7.	   6	   0.68	   13	   PICU	   Klebsiella	  sepsis,	  septic	  shock	  
	  	  	  8.	   4	   0.23	   22	   Previously	   Pneumonia,	  CMV	  
	  	  	  9.	   2	   0.92	   2	   No	   Pneumococcal	  meningitis	  
	  	  	  10.	   3	   0.59	   17	   PICU	   H1N1	  Pneumonia	  
	  	  	  11.	   3	   0.28	   26	   PICU	   PCP	  /	  rhinovirus	  pneumonia	  
	  	  	  12.	   2	   0.09	   26	   PICU	   PCP,	  Klebsiella/	  pseudomonas	  sepsis	  
	  	  	  13.	   2	   0.14	   16	   PICU	   PCP,	  RSV,	  parainfluenzae	  
	  	  	  14.	   2	   0.46	   1	   Previously	   Pneumococcal	  meningitis	  
	  	  	  15.	   5	   0.16	   3	   Previously	   Klebsiella	  sepsis,	  
	  	  	  16.	   7	   0.25	   17	   PICU	   CMV,	  RSV,	  MRSA	  sepsis	  
	   	   	   	   	   	  
	  
	  
Table	  5	  shows	  the	  characteristics	  of	  the	  7	  HIV	  infected	  children	  who	  died	  in	  the	  hospital	  ward	  
following	  a	  PICU	  admission.	  The	  majority	  of	  these	  children	  died	  from	  respiratory	  failure.	  
Another	  child,	  who	  had	  commenced	  ARV’s	  in	  PICU,	  died	  following	  PICU	  discharge.	  One	  child	  
died	  prior	  to	  the	  initiation	  of	  ARV’s.	  Six	  of	  the	  HIV	  infected	  children	  who	  died	  following	  PICU	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Diagnosis	  /	  Cause	  of	  
Death	  
Days	  post	  PICU	  
discharge	  
1	   78	   16	   Previously	   Chronic	  lung	  disease	   1	  
2	   14	   9	   Previously	   Myocarditis	   3	  
3	   7	   42	   PICU	   Chronic	  lung	  disease	   2	  
4	   2	   3	   No	   Pneumonia	   13	  
5	   1	   24	   Previously	   Klebsiella	  Septicaemia	   5	  
6	   4	   6	   Previously	   Pneumonia,	  PCP	   31	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DISCUSSION	  
This	  retrospective	  review	  focused	  on	  critically	  ill,	  HIV	  infected	  children	  admitted	  to	  a	  paediatric	  
intensive	  care	  unit	  in	  a	  developing	  country,	  who	  were	  commenced	  on	  antiretroviral	  medication	  
as	  soon	  as	  logistically	  possible	  and	  empirically	  started	  on	  gancyclovir	  for	  suspected	  CMV	  
infection.	  The	  survival	  rates	  of	  HIV	  infected	  children	  in	  our	  institution	  have	  increased,	  with	  
79%	  of	  children	  surviving	  the	  PICU	  admission	  and	  69%	  of	  the	  children	  surviving	  to	  hospital	  
discharge.	  We	  managed	  to	  initiate	  ARV’s	  in	  PICU	  in	  61%	  of	  children	  eligible	  for	  ARV’s.	  CMV	  was	  
a	  common	  opportunistic	  infection	  and	  a	  high	  CMV	  viral	  load	  was	  found	  in	  nearly	  60%	  of	  
children	  not	  previously	  on	  ARV	  medication.	  At	  least	  60%	  of	  the	  children,	  who	  were	  discharged	  
home,	  or	  89	  %	  of	  the	  children	  with	  follow	  up	  data,	  were	  known	  to	  be	  alive	  1	  year	  later.	  	  
	  
Sub-­‐Saharan	  Africa	  has	  been	  the	  epicenter	  of	  the	  HIV	  epidemic	  (32).	  The	  numbers	  of	  children	  
with	  HIV	  have	  overwhelmed	  healthcare	  systems	  and	  increased	  the	  South	  African	  under	  5	  year	  
mortality	  rate	  (10).	  A	  large	  PICU	  in	  London	  (13)	  only	  admitted	  42	  HIV	  infected	  children	  in	  a	  ten	  
year	  period,	  which	  poignantly	  reflects	  the	  difference	  in	  disease	  burden	  faced	  by	  developing	  
countries.	  Intensive	  care	  is	  an	  expensive,	  scarce	  resource	  in	  developing	  countries,	  and	  rationing	  
resources	  (28,33,34)	  is	  a	  daily	  reality,	  which	  increases	  the	  emotional	  burden	  on	  clinicians	  
caring	  for	  critically	  ill	  children	  with	  a	  high	  likelihood	  of	  dying.	  
	  
HIV	  infection	  in	  childhood	  is	  preventable	  with	  access	  to	  medical	  care	  and	  appropriate	  
interventions.	  According	  to	  the	  UNAIDS	  2014	  report	  (32),	  between	  2009	  and	  2013,	  there	  has	  
been	  a	  43%	  decline	  in	  the	  number	  of	  new	  HIV	  infections	  in	  children,	  mainly	  as	  a	  result	  of	  HIV	  
infected	  pregnant	  mothers	  receiving	  ARV	  medication	  and	  effective	  PMTCT	  programmes.	  In	  our	  
cohort	  of	  children,	  only	  29%	  of	  the	  HIV	  infected	  children	  were	  known	  to	  have	  been	  on	  the	  
PMTCT	  programme.	  However,	  it	  is	  likely	  that	  this	  is	  an	  underestimation,	  as	  PMTCT	  was	  not	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documented	  in	  the	  folders	  of	  36%	  of	  the	  HIV	  infected	  children.	  It	  is	  concerning	  that	  35%	  of	  HIV	  
infected	  children	  did	  not	  receive	  PMTCT,	  which	  most	  likely	  reflects	  the	  challenges	  women	  face	  
in	  accessing	  antenatal	  care	  and	  the	  deficiencies	  in	  our	  healthcare	  system	  (16).	  
	  
Developed	  countries	  introduced	  ARV	  therapy	  in	  the	  early	  1990’s	  (35,36),	  whilst	  the	  huge	  
burden	  of	  disease,	  cost	  of	  ARV	  therapy	  and	  political	  intrigue	  only	  saw	  ARV	  therapy	  introduced	  
by	  the	  South	  African	  government	  in	  2003.	  Our	  review	  focused	  on	  children	  admitted	  to	  PICU	  in	  
2009,	  a	  period	  in	  which	  eligibility	  for	  ARV	  therapy	  was	  based	  on	  clinical	  and	  immunological	  
criteria.	  	  
	  
Antiretroviral	  drug	  therapy	  has	  subsequently	  become	  standard	  treatment	  for	  HIV	  infected	  
children	  (37).	  The	  2013	  guidelines	  from	  the	  Department	  of	  Health	  in	  South	  Africa	  (38)	  
recommend	  that	  all	  children	  under	  5	  years	  of	  age	  are	  eligible	  for	  ARV	  treatment	  irrespective	  of	  
their	  CD4	  counts.	  Furthermore,	  children	  less	  than	  1	  year	  of	  age,	  children	  with	  WHO	  stage	  4	  
disease,	  children	  with	  drug	  resistant	  TB	  and	  with	  CD4	  counts	  less	  than	  15%	  should	  be	  fast	  
tracked	  and	  start	  ARV’s	  within	  7	  days.	  A	  Cochrane	  review	  (39)	  of	  the	  effectiveness	  of	  ARV	  
therapy	  in	  HIV	  infected	  children	  under	  2	  years	  of	  age,	  only	  included	  2	  studies	  in	  order	  to	  
address	  the	  question	  of	  when	  to	  start	  ARV	  treatment.	  Their	  recommendations	  were	  in	  keeping	  
with	  the	  included	  CHER	  study	  (18),	  advocating	  early	  ARV	  therapy	  in	  infants	  to	  prevent	  
progression	  of	  disease	  and	  early	  death.	  The	  recommendations	  for	  initiating	  ARV	  therapy	  in	  
children	  less	  than	  2	  years	  of	  age	  are	  less	  clear,	  however	  it	  is	  recognized	  that	  they	  have	  a	  high	  
risk	  of	  dying.	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However,	  there	  is	  little	  published	  data	  on	  initiating	  ARV	  drugs	  in	  critically	  ill	  children	  in	  PICU.	  
Cowburn	  et	  al	  (11)	  reported	  the	  experience	  	  of	  initiating	  ARV	  treatment	  in	  children	  following	  
PICU	  discharge.	  ARV	  therapy	  was	  only	  initiated	  in	  21	  of	  the	  51	  children	  who	  survived	  the	  PICU	  
admission,	  with	  11	  of	  these	  children	  known	  to	  be	  well	  almost	  1	  year	  later.	  Thirteen	  children	  
died	  in	  the	  wards	  before	  commencing	  ARV’s,	  11	  children	  did	  not	  meet	  the	  criteria	  for	  
commencing	  ARV’s	  and	  4	  children	  were	  lost	  to	  follow	  up.	  	  
	  
We	  only	  managed	  to	  initiate	  ARV	  therapy	  in	  31	  (61%)	  children	  eligible	  for	  ARV	  therapy	  during	  
their	  intensive	  care	  stay.	  This	  was	  mainly	  related	  to	  a	  shorter	  PICU	  stay	  in	  this	  group	  of	  patients	  
and	  logistic	  factors	  like	  delays	  in	  confirmatory	  HIV	  results	  and	  counseling	  of	  care-­‐givers.	  It	  is	  
reassuring	  that	  all	  children	  who	  survived	  the	  hospital	  admission	  were	  discharged	  home	  on	  ARV	  
medication	  and	  hugely	  encouraging	  that	  89%	  of	  the	  children	  with	  follow	  up	  data	  was	  alive	  1	  
year	  later.	  There	  are	  many	  gaps	  in	  our	  health	  system	  (40)	  	  and	  another	  major	  challenge	  is	  
ensuring	  that	  children	  starting	  ARV	  medication	  receive	  the	  appropriate	  follow	  up	  and	  support	  
for	  this	  life	  long	  chronic	  illness.	  	  
	  	  
The	  only	  complication	  related	  to	  initiation	  of	  ARV	  medication	  in	  this	  cohort	  of	  patients	  was	  
IRIS.	  Twenty	  –nine	  percent	  of	  the	  children	  who	  commenced	  ARV’s	  either	  in	  PICU	  or	  
subsequently	  the	  ward	  developed	  IRIS,	  with	  BCG	  adenitis	  occurring	  slightly	  more	  commonly	  
that	  pulmonary	  tuberculosis	  (some	  had	  AFB’s	  isolated	  on	  sputum,	  but	  mostly	  on	  CXR	  changes	  
and	  symptoms	  -­‐	  treated	  empirically	  by	  the	  infectious	  diseases	  team).	  South	  Arica	  has	  one	  of	  the	  
highest	  incidences	  of	  Tuberculosis	  in	  the	  world	  (41)and	  HIV	  infected	  children	  are	  particularly	  
susceptible.	  Walters	  (27)	  reviewed	  290	  HIV	  infected	  children	  receiving	  ARV’s	  over	  a	  2-­‐year	  
period	  and	  reported	  that	  48%	  of	  the	  children	  were	  treated	  for	  tuberculosis.	  The	  high	  burden	  of	  
tuberculosis	  and	  susceptibility	  of	  HIV	  infected	  children	  is	  illustrated	  by	  116	  episodes	  of	  TB	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diagnosed	  before	  the	  children	  commenced	  ARV’s	  and	  only	  21	  episodes	  of	  TB	  diagnosed	  after	  
initiating	  ARV’s.	  Smith	  et	  al	  (42)	  prospectively	  followed	  up	  a	  group	  of	  HIV	  infected	  children	  
commencing	  ARV’s,	  found	  that	  21%	  of	  children	  developed	  IRIS	  at	  a	  median	  of	  16	  days	  post	  ARV	  
initiation.	  BCG	  adenitis	  and	  pulmonary	  tuberculosis	  was	  the	  commonest	  reactions,	  and	  they	  
also	  described	  cases	  of	  CMV	  pneumonia,	  streptococcus	  pneumonia	  and	  seborrheic	  dermatitis.	  
The	  development	  of	  IRIS	  was	  associated	  with	  younger	  children	  and	  children	  with	  low	  CD4	  
counts.	  	  
	  
Puthanakit(43)	  reported	  the	  incidence	  of	  IRIS	  to	  be	  19%,	  in	  a	  group	  of	  children	  in	  Thailand	  
with	  advanced	  HIV	  commencing	  ARV’s.	  Apart	  from	  IRIS	  secondary	  to	  mycobacterial	  organisms,	  
Puthanakit	  also	  described	  reactions	  to	  Herpes	  simplex	  virus,	  Cryptococcus	  neoformans	  and	  an	  
episode	  of	  Guillain	  Barre’	  syndrome.	  The	  children	  in	  this	  study	  who	  developed	  IRIS	  had	  lower	  
baseline	  CD4	  counts,	  compared	  to	  the	  children	  who	  did	  not	  develop	  IRIS.	  Rabie(44)	  reported	  a	  
substantial	  reduction	  in	  the	  risk	  of	  developing	  BCG-­‐IRIS	  in	  children	  who	  initiated	  ARV’s	  under	  
12	  weeks	  of	  age	  compared	  to	  children	  who	  only	  started	  ARV’s	  once	  they	  had	  deteriorated	  
immunologically	  or	  clinically.	  	  
	  
The	  HIV	  infected	  children	  who	  commenced	  ARV’s	  in	  our	  cohort	  had	  very	  low	  CD4	  counts	  and	  
were	  all	  severely	  immunosuppressed.	  This	  might	  explain	  the	  higher	  incidence	  of	  IRIS	  in	  our	  
cohort	  compared	  to	  previous	  studies.	  The	  reported	  mortality	  with	  IRIS	  is	  relatively	  low,	  and	  in	  
our	  setting	  the	  benefits	  of	  early	  initiation	  of	  ARV	  medication	  on	  long-­‐term	  survival	  is	  of	  greater	  
importance.	  None	  of	  the	  HIV	  infected	  children	  admitted	  to	  PICU	  on	  ARV	  therapy	  were	  
diagnosed	  with	  IRIS,	  which	  is	  probably	  more	  reflective	  of	  our	  understanding	  of	  the	  condition.	  A	  
recently	  published	  systematic	  literature	  review	  on	  tuberculosis	  IRIS	  only	  identified	  13	  studies,	  
highlighting	  the	  lack	  of	  information	  and	  our	  limited	  understanding	  of	  this	  phenomenon(45).	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PCP	  has	  been	  the	  most	  commonly	  associated	  opportunistic	  infection	  in	  HIV	  infected	  
children(22,23).	  We	  only	  isolated	  PCP	  in	  25%	  of	  HIV	  infected	  children	  presenting	  with	  
pneumonia.	  Due	  to	  the	  limitation	  of	  the	  PCP	  immunofluorescence	  test,	  all	  our	  HIV	  infected	  
children	  with	  severe	  pneumonia	  were	  treated	  for	  suspected	  PCP	  with	  21	  days	  of	  cotrimoxazole	  
and	  prednisone,	  irrespective	  of	  the	  immunofluorescence	  test	  result.	  Morrow	  et	  al	  (46)	  recently	  
demonstrated	  a	  2.5	  times	  increased	  diagnostic	  yield	  using	  a	  PCP	  PCR	  compared	  to	  
immunofluorescence	  testing	  and	  using	  a	  Grocott	  stain.	  
	  
The	  diagnosis	  of	  CMV	  infection	  in	  children	  is	  also	  problematic.	  A	  lung	  biopsy	  is	  the	  gold	  
standard	  for	  diagnosing	  CMV	  pneumonitis,	  but	  is	  often	  not	  feasible	  in	  ventilated	  children	  with	  
severe	  pneumonia.	  Chintu	  et	  al(47)	  reported	  the	  post	  mortem	  findings	  of	  a	  group	  of	  HIV	  
infected	  Zambian	  children	  who	  died	  from	  pneumonia,	  finding	  histological	  evidence	  that	  29%	  of	  
the	  children	  had	  PCP	  and	  22%	  of	  them	  had	  CMV	  pneumonitis.	  Goussard	  et	  al(24)	  reported	  the	  
lung	  biopsy	  and	  post	  mortem	  histology	  of	  a	  group	  of	  HIV	  infected	  children	  admitted	  to	  a	  PICU	  
with	  severe	  pneumonia,	  finding	  that	  72%	  of	  them	  had	  histological	  evidence	  of	  CMV	  disease	  and	  
the	  pp65	  antigen	  for	  CMV	  was	  falsely	  negative	  in	  24%	  of	  children.	  Kitchen	  et	  al(26)	  reported	  on	  
the	  outcomes	  of	  63	  HIV	  infected	  and	  exposed	  children	  admitted	  to	  PICU	  with	  ARDS,	  finding	  
positive	  PCP	  tests	  in	  33%,	  a	  CMV	  viral	  load	  greater	  than	  log	  4.0	  in	  38%	  	  of	  children	  and	  a	  
mortality	  rate	  of	  30%.	  Zampoli	  et	  al	  (25)	  investigated	  the	  prevalence	  of	  CMV	  associated	  
pneumonia	  in	  hospitalized	  children	  using	  quantitative	  CMV	  PCR	  ,	  using	  a	  cut	  off	  of	  greater	  than	  
4.0	  log	  copies/ml	  to	  indicate	  a	  high	  CMV	  viraemia.	  Overall,	  they	  reported	  CMV	  associated	  
pneumonia	  in	  28%	  (47/169)	  of	  children,	  with	  a	  prevalence	  of	  36%	  in	  HIV	  infected	  children	  
compared	  to	  15%	  in	  immune-­‐competent	  children.	  In	  this	  study,	  HIV	  infected	  children	  with	  CMV	  
associated	  pneumonia	  had	  a	  much	  higher	  mortality	  rate	  than	  immune-­‐competent	  children.	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Hsiao	  et	  al(29)	  investigated	  the	  prevalence	  of	  CMV	  viraemia	  in	  asymptomatic	  HIV	  exposed	  
infants	  and	  compared	  them	  to	  HIV	  exposed	  children	  hospitalized	  with	  pneumonia.	  They	  
showed	  that	  HIV	  exposed	  children	  hospitalized	  with	  pneumonia,	  had	  significantly	  higher	  CMV	  
viral	  loads	  than	  asymptomatic	  HIV	  exposed	  children,	  with	  CMV	  viral	  loads	  peaking	  at	  3	  –	  4	  
months	  of	  age.	  
	  
In	  children	  admitted	  to	  our	  PICU	  with	  severe	  pneumonia,	  we	  considered	  a	  CMV	  viraemia	  of	  
greater	  than	  4.0	  log	  copies/ml	  indicative	  of	  CMV	  pneumonia.	  Thirty-­‐eight	  percent	  of	  children	  
admitted	  on	  ARV’s	  had	  a	  positive	  CMV	  viral	  load,	  and	  57%	  of	  the	  HIV	  infected	  children	  not	  on	  
ARV’s	  on	  admission,	  had	  a	  positive	  CMV	  viral	  load.	  The	  decision	  to	  empirically	  start	  gancylovir	  
in	  critically	  HIV	  infected	  children	  admitted	  to	  our	  PICU	  was	  taken	  on	  the	  context	  of	  the	  high	  
prevalence	  of	  CMV	  disease	  in	  immunosuppressed	  children	  and	  the	  reality	  that	  CMV	  viral	  load	  
results	  were	  only	  available	  3	  -­‐5	  days	  after	  the	  tests	  were	  requested.	  
	  
We	  also	  isolated	  a	  number	  of	  respiratory	  tract	  viruses	  in	  conjunction	  with	  PCP	  and	  CMV	  from	  
HIV	  infected	  children	  admitted	  with	  respiratory	  failure.	  In	  this	  setting,	  it	  is	  almost	  impossible	  to	  
say	  how	  these	  viruses	  are	  contributing	  to	  the	  lung	  disease.	  	  
	  
CMV	  enteritis	  was	  diagnosed	  histologically,	  and	  with	  a	  high	  CMV	  viral	  load,	  in	  2	  children	  who	  
presented	  with	  intestinal	  perforation	  and	  necrotic	  bowel.	  These	  children	  were	  not	  established	  
on	  ARV	  therapy,	  as	  no	  intravenous	  preparations	  are	  available.	  Treatment	  was	  withdrawn	  in	  
both	  children	  because	  of	  ongoing	  bowel	  necrosis.	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The	  overall	  PICU	  and	  hospital	  survival	  rates	  in	  our	  retrospective	  study	  is	  encouraging	  and	  an	  
improvement	  on	  that	  reported	  previously	  from	  our	  institution	  (11,48).	  The	  individual	  child’s	  
risk	  of	  dying	  ultimately	  depends	  on	  the	  severity	  of	  their	  underlying	  illness.	  This	  is	  usually	  not	  
clear	  not	  admission,	  as	  the	  disease	  is	  still	  evolving	  and	  the	  exact	  underlying	  condition	  is	  often	  
not	  fully	  defined.	  Two-­‐thirds	  of	  the	  HIV	  infected	  children	  in	  our	  cohort	  had	  a	  discharge	  
diagnosis	  of	  pneumonia,	  with	  76%	  of	  these	  children	  surviving	  to	  hospital	  discharge.	  Whilst	  all	  
the	  children	  diagnosed	  with	  CMV	  enteritis	  and	  pneumococcal	  meningitis	  unfortunately	  died.	  	  
	  
Study	  limitations	  -­‐	  the	  data	  was	  collected	  retrospectively	  and	  limited	  to	  what	  was	  recorded	  in	  
patient’s	  clinical	  notes.	  The	  study	  design	  is	  not	  able	  to	  prove	  whether	  the	  increased	  survival	  of	  
HIV	  infected	  children	  is	  related	  to	  the	  early	  initiation	  of	  ARV	  medication	  and	  empiric	  
gancyclovir	  treatment.	  However,	  with	  the	  improvements	  in	  general	  PICU	  care,	  mortality	  rates	  
of	  most	  diseases	  are	  decreasing.	  	  	  	  
	  
CONCLUSIONS	  
This	  retrospective	  study	  shows	  that	  increasing	  numbers	  of	  critically	  ill	  HIV	  infected	  children	  
are	  surviving	  PICU	  and	  hospital	  admissions.	  Antiretroviral	  therapy	  was	  successfully	  initiated	  in	  
PICU	  and	  apart	  from	  the	  risk	  of	  IRIS,	  there	  were	  no	  obvious	  side	  effects	  to	  commencing	  ARV’s	  in	  
critically	  ill	  children.	  CMV	  is	  a	  common	  opportunistic	  infection	  in	  HIV	  infected	  children	  and	  
empiric	  therapy	  with	  Gancyclovir	  should	  be	  considered	  whilst	  confirmatory	  blood	  results	  are	  
awaited.	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APPENDICES:	  
	  
Appendix	  1:	  	  Data	  Collection	  Sheet	  
	  





Sex:	   	  	  	  male	  /	  female	  
	  
Age	  on	  admission	  to	  PICU:	  	  
	  
Reason	  for	  admission:	  elective/	  respiratory	  failure/	  septic	  shock/	  neurological/	  other	  	  
	  
Admitted	  from:	  community	  /	  other	  hospital	  /	  RXH	  hospital	  ward/	  emergency	  unit	  	  
	  
Hospital	  admission	  date:	  
	  
PICU	  admission	  date	  
	  
History	  of	  PMTCT:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  yes	  /	  no	  /	  unknown,	  	  	  	  	  	  	  	  	  	  if	  no,	  why	  not:	  	  
	  
HIV	  diagnosis	  date:	   	  
	  
Admission	  weight:	   	   	   	   	   	  
	  
PIM2	  /	  Predicted	  mortality:	  
	  
Ventilation:	  	  	  	  	  date	  intubated:	  	  	  	  	   	   	   	   date	  extubated:	  
	   	   	  	  
Folder	  No:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (	  
	  
	  
	   30	  
	   	   	  	  	  non-­‐invasive	  ventilation	  /	  cpap:	  	  date	  started:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  date	  stopped:	  
	  
CD4	  count:	  	  	  	  absolute:	  	  	  	   	   	   %	  
	  
CMV	  viral	  load	  /	  PCR:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  copies	  /	  ml	  	  	  	  	  	  	  	  log	  10	  
	  
Date	  ARV’s	  started:	   	  
	  
PICU	  survivor:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   yes	  /	  no	  
	  
Treatment	  limited/withdrawn	  in	  PICU:	   yes	  /	  no	   	  
	  
PICU	  discharge	  date:	  
	  
PICU	  discharge	  diagnosis:	  
	  
Hospital	  ward	  death:	  	   	   	   yes/	  no	  	  	  	  	  	  	  	  	  if	  yes,	  Date:	  
	  
IRIS/	  complications	  related	  to	  ARV’s:	  	   yes	  /	  no	  	  	  	  	  	  	  	  if	  yes,	  Details:	  
	  
Hospital	  discharge	  date:	  
	  
12	  month	  follow	  up/	  outcome:	  	   	   alive	  /	  dead	  /	  unknown	  /	  referred	  CHC	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Dear Dr Solie, 
Dr TA Blo ke 
C hairperson Hospital Researc h Review Committee 
Em ail : thomos.blake@westemca pe .gov .za 
Tel: +27 2 1 6585788 fax: +27 21 658 5166 
22 October 2014 
RE: RESEARCH: Paedia tric Intensive Core outcomes of HIV Infected children In a developing 
country 
You may proceed with the above-mentioned study. 
Yours faithfully, 
DR TA BLAKE 
CHAIRPERSON 
HOSPITAL RESEARCH REVIEW COMMITIEE 
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Appendix	  4:	  Pediatric	  Critical	  Care	  Medicine	  :	  Instructions	  for	  Authors	  
	  
PI/Ji«tric Oitkal C.,.. Mtdici,.- is a:n int.ema. 
tional, pe,er.n-riewcd juumal that U ~
in publishing the h.ish,e=rt qudty Kimtific 
.rtudics in the fidd of pc.di.nric criticaJ cue 
meclkinc. 
MANUSCRIPT SUBMISSION 
M.unascripts :ui: $ubmitted throagb llclitoriaJ 
Mula~. a \\~ m,;anuscripl tucking 
.$)'.Jtcm in use by SCCM. This $fSlffll allows 
autbon to add a ,-m,;anwcripl o, ch«k th,,: 
.$btW of a .dimititd m.ml»C'.ripl. while .diort.. 
ming th,,: time nttded for proceu.ing ma:n.u.-
$ctipts in the Ediwial 08ioe and through ptff 
~ icw. lo dmit mmwcripts fu, ~ . 
mun. go to wwwxcm.org. COOO$C fh:liatric-
Oitiar.l C4rl' Mtdicir,t under the Publkalions 
tab. then sdcd "Submit Ma:nwcripu.. ~ Onoe 
)'OU reach th,,: Ediwial Ma~ home pall(. 
k,g on to th,,: 5fJtcm br cruting an ao:uunl o, 
entering through JOW' existing :aca,u:nt. 
llclitoriaJ Manag,e,,4 wiU euily guide :u 11hors 
through the m.mU!C'.ript $ubmilllion ~ 
Requiml infurmmun pertaining to the m#I· 
U!C'.ript includes th,,: !WM. :addt-. tdq,bcmc 
number. and e.m;ail :addtt. fo, the 6m auth« 
a:nd aU contributing authors; affiti.ncd imtitu.-
oon,. title of the ffl#luscript;; abc.ia: and key 
wonk If authors widl, they m,;i.y p,ovidc op-
tional infurmation th.it includes auth«0$ sug. 
ecstcd rcvicwctS and authot"s nonP'cfcr~ 
~ icwien. The Editorial Offi« wiD :wtom.1ti. 
arty be notified of the dmiJIQIJtl and ,.; 11 
$did an ,:. mail amfuminit the subm.-ion of 
the manu,cripc to the autbor(s). Aftt.r cdito--
ri:d officc tt'\'K'W of the $ubmitted dowmmt4 
a manu,cripc number will be :a.S!Qgnecl to CS1ch 
$ubmitted m.mU!C'.ripl. which will be used in 
all CIIHTOp 1dcnc.c. 
E:ach fflUIWCripl submilllion $bould dcsignat.e 
one co1TCSpunding auth« :and all amtribut.-
ing ~ The n.umbcr of autbon dlouJd be 
RlClricti:d to only lOOik" pcnons wbo baaYi: truly 
p,uticipat.ed in the omccption. design. acaJ..-
tion. a:nd writing of the mmwcripL Authors 
m111l d iscl<»e any polffltial financial o, dl.aJ 
conllicu of inwe.11 tquding the conten ts of 
the .dimiuion. 
scx:>.i w:q,ts no R$pc.¢1$ibility fu, ma:n.u.-
$ctipts that ate bl or de.cuoycd through 
c:kdronk o, computer problems. Authors 
ate mcou,'~ to keep copies of $ubmitt.ocl 
manu,cripu. including 6gura ff an auth« 
d,:,cs noc ~""' amlirmation of submilllion 
into Editori:iJ M.u.~ within two d:iys. h,,: 
or sh,,: dloulcl omtad the £.ditorial Office .it -
Copyruhr. F.ach author must a,mpkti: and 
$ubmit the journal's a,pyrigh1 tnruf'er 
agn,em,mt. which includes a s«tion on the 
ducbuti: of pc,t.mtial a.nllicts of inli:Rlsl 
b.ucd on th,,: R'Ulfflmendalions of the In. 
LffllationaJ Committ« of Medical JollnW 
llcliton:, 91.JnOOffll Rcquirml,mts for Manu.-
$ctipts Submitted to BiDmcdial }oumals" 
( www.icmjc.«it/update.!.tm0 . Tbeform must 
be, c.ompleud. by c.cb autbM ud must be 
uplo.ackd with youtodicr .un-=ript docu.-
mmu al the time af w bmilAOn. The »rm is 
A!Wity :rv#lable on the m,;anwcript.dimiuion 
~ http://www.«litoriaJm.inaec,.comfp:cm 
a:nd mllQ be compktcd a:nd submitted d«--
tronicaUy. Plcuc note that authors may 
.sign th,,: wpyrig!.1 ttfflllli.-r agri:cmcn1 form 
d«uonicaly. For :additional information 
about dectronicaUy lligt,ing this form, i,:i to 
httfX/Jlinh.hnc.com/1..UAT/ A 106. 
Ci,miJ.ill...-t> With NIH .,.J ~ .r Rau.ml 
p..,J;Jff Ag,n,q Attt.U10J1iJy Rl'lf.Kirm,,n"s. 
A n.umbcr of ,,:,,c,eard. funding ~cits now 
noquin: or noqucst :wthon: to dmit th,,: po=rt.. 
print (th,,: attick alter ptff review and aoc,cp--
tui« bul not th,,: ~ publehed attidc) to a 
rq,osiwy that U aocieuibk online br all with. 
Olli ch#gc. Ju a servioe to ow authors. LWW 
wiD iclmtify to th,,: National Libtuy of Medi. 
cine ( NLM) attidcs that ttquiti: d,:pMit and 
wiD t.nmmit the po11t. prim of :u. article~ 
on ttJCard. funded in wbolc o, in put br the 
National lm tiwtcs of Hci1th, Wdbmc Trust. 
Howatd Hughes Medical lnstitu~ °' oth.ct 
funding ~cits to Pub..\.ltd Cmtral The tt.-
viM'd Copyright Traruf'ct Ag,ccmcnl p,ovicb 
the mcd.anism. 
F;.,.,.,;,J DiK1-A" flJIJ C:O..jlim of !,ita-. 
m. Authon: must $Ulc :dJ po,!'ibk amllkts 
of in terest in the ma:nu.u:ripc. including fimn. 
cial, co..uhant. i..iit'Ution.& and oth.ct teb.-
1:iomhips that mig!.1 lcw:i to biu « a amllict 
of i111cRlst.. If there is no conflict of inlffffl. 
this sboulcl aho be cxp5citfy $tmd as oonc 
declan'JCI. All toUtCCl$ of funding $bould be 
ad.:nowkdgcd in the ffl#lusctipL AD tdcorant 
amllkts of il?lcfel :and - of funding 
.sbmtld be induded on the title paftt of the 
mamJKript with th,,: 11.Nding "CDnllkts of 
l111c1'et and Soutcc of Ftlncling."' For CIQ.fflplc: 
Cnnllkts of ln\ffl!.11 a:nd Souroe of ftlncl. 
ing: "'Autbot A"' b• rco:i'rl:d OOnonria from 
"'Compu.y l.~"'Author B'"' Ucunmtfyrco:i'ring 
a gta:nt (1"12345) from "'Org.u.iution Y.~ and is 
on the speaker's bu:miu fut "Orpniutinn X" 
- tbcCMEotga:niunfutCompu.y I. For the 
mnaining autbon noncwettdcdued. 
n ... -,. 11""1 Mim.J S.ft..,ittu. AU fflldics of 
h.umu. subjects must contain a sut.emmt 
with.in the M.ucriak :and Methods s«tion 
indiating a~ of the study br the I.Nb+ 
t'tJtiDm1 R.c,oriew 8oud (or inaitu:tional tt.-
vicw body) tha1 $ul.j,:cts ha¥C lligncd written 
infunne.d ca,m,ent. or th.u the lnstit'Utioiwl 
Review Board w.tived the need fut informed 
CIIIIUCUl. &/oA" ,out submi.aio11 can be aclrt 
out for pttt ttYiitw, ii i• fl«oMfT that you 
ado!tc. this 1-uc af ilutitutiM.al rcricw ap. 
pnwal This is in :aca,nb.nc,: with the l.tllerN--
t:ionaJ Cnmmitttt of Ji,umal Editms uniform 
rc,quitcmcmJ f« manu,cripts dmitted to 
bium«lical juwN.ls.. Please .k'C http:llwww • 
icmie,org fot mote details. All :u.imd studies 
must con.lain a .sbtcmcnt within the M:.ltffl • 
als and }.kt.hods .k'diDn confirming a~ 
by th,,: lnrtitutiDnal Animd Catt and llic 
Cnmmitttt and that the cue and handling 
of the a:nimah were in accord with N.uioiwl 
lnstit'Utc$ of Jiwtb gu:iddincs « o ther in-
t.emation.Jly tewgn..ix,:d guideline fu, cth.ial 
animal lnlltrnmL 
St•WtiuaJ ~ . Any $!Udy amtain.ing 
quantituiwi: dab a:nd N tistical infcn:ncc 
$bould be ~ by a comulbnl with fut. 
mal sut:irtical training a:nd o:ptrimoe. 
MANUSCRIPT PREPARATION 
M:.ulwcripts mwl confunn to Paniwit Om. 
o J 0.11' MtdidM lnstrtldilJru for Autbon 
ancl/ot the"'Llniform Rc,qairmw:nts fut Manu.. 
.scripts Submitted to Binmedia1 Journals," 
wh.id. Qn be found cm th,,: lnten..;atioiwl 
Cnmmitttt of Medial }oumal Editoff Web 
$ne. www.icmic.ont:. MamJKric,ts must be 
~ withpagcsnumbmd~ 
ti¥dy, beginning with the title, p,:igc. Each pu.a.. 
graph should be indcntocl with a tab. The text 
portiDn of each ma:nu.u:ripc dlouJd be in Mi. 
crmoft Word '»mat. induding td'crma,: and 
hgwe kgmck.F',gu,cs can be sa¥l'd in .tif or 
.cp, fotm.n in 300 dpi °' higher. T.mlcs Jhould 
be submitted u Micrmofi Word files; Jptead.. 
$beds uc nDl accq,lllbk. Pigwes .sbmtld be 
.sll'll!'ld u sq,u.nc hies and upbd«I ancr the 
tat ~ is compltt.c. Sp«:ific guidelines fut 
hgwe formatting ue found on the Editorid 
~home~ Documents submitted 
in .pdf fotm.n an: noc acupublc. 
Whm uplcN,::ling th,,: tat. tablcc. and figw cs 
into Editori:iJ Manag,e,,4. thett U the option of 
entering hies fut n"'ricw a:nd hies fut produe. 
t:ion. Piles for tt'¥K'W an: viewable by the cdi~ 
rial mfr. the «litot. a:nd the t~~ These 
documents dloulcl indudc all text. tables, 
and figt!RlS, • wdl u any ¢al td'etfflt'.C'd 
malff'ial Files fut produdinn ate only seen 
by th.c cditoNJ .sbff' a:nd wiD noc be $C'C!, by 
rcvicwctS. 
	  




nd,- Pfff'". The title p;age .diould a,nbin I) 
the title; 2) fir,a name, middle initiil ;a:nd Jut 
iwrneof each author. 3) highest aadc:mic de.-
~ li:lowdup dmgmtiDru. and iNtiwt:m. 
al :affiliation for w:h wthor, 4) name of th.e 
inrtil'utiDn(s) whett th.ewotk w.u ~ -
5) th.e :addtt,;s for reprint:! and a $lmmml rcs-
gatding wlwthff reprints wil be ordered: and 
6) hn.#lcial $upporl uK'!d b th.ertudy. indud. 
ing any inrtitutiDnal departmental funck. The 
autooff $OOU)d also p-oriclc six kq words few 
indo:ing. using tcrmJ from the Medial Sub. 
j«t Headings lisa of IIWX MtJitw. Strudt&R'd 
abmxts ue ttquiml for aU ma:nu.u:ripts (c,;. 
a-pt «lillllriah. ldttt5. and book~) wb.-
mitt.ed to fh:liatric-CritialJ C4tl' Mtdici11t. 
£ditorii1 Mana~ ,.; 11 prompt authors to 
inpu1 th.e :above iioormation into specific 
fidcls as thq arc submit.ting tlwir mfflWIC'.ripL 
Authon $bowd aho uploul their tit.le pag,e 
a:nd $tnlCl'w'ed :absanct with the body of their 
maffllKfipt. It U aho importan1 to note th.it 
if th.ere is fCH'ffA.tt.ocl text ot Ctfflt lcttcrs o, 
.$)'fflbols in the title °' wstr.lct. ~al coding 
is n«-ur and th.e O.anida' Paldt.e in Edi. 
t.uriiJ Mln.igcr9 will ni:«I to be uud. 11 ismt 
~ to coi:k sp«ial duinzercn «iwl jorrMb 
intlwatttt.cal~ 
A.lmr.rb, Ab.trads should be ni, more ~ 
300 wonb in length and must ~vc th.e fol. 
lowing beadings: Objt'diwc. Ocsi!VI, Sdting. 
Patients (lo, Cl mal ln't'C$lip tion,.) °' Sub. 
~ (for Labor.ltoty l.n¥CStigat:ions) , Int.er. 
vmtion:c, Mcu'urffl!fflts and Main Rcsulu. 
a:nd Gondwimu. Rc<riew papctS and special 
articles .di.mdd use these beulinp in the :ab.-
mart Obj«tiv,r,. Dab SouteeS, Study Sd«--
t:ion. Dau I.unction. Dlta SyntbCAs. and 
~ For &-tam rqptding the prq,o. 
ration of urudutl:d abrtrxu,. refer to th.e 
AmC'TKa1t Mtdkal A.uodat.icui Mamu1J cf 59{t. 
lemb Edition (p. 20.23). 
11-.d M11fffial The text fflould be o,pniud 
into the lollDwi.ng.KdionJ: lntrodudiun, Ma. 
t.criah :and Md.hoclJ. Results. Oi,c:uuion. and 
~ foOowcd by AdoowlcdgmmtJ. 
Rcfcn-no:,s, Figure Lc,g,mck. and Table.c.. Sec--
marial and editmial uri.m.n« ue not :ac--
knowte,d~ Results mir be pre.ciented in th.e 
tat. in tf.c figwu. or i.n the tables. The J:>u. 
aw:io.n J«t:io.n JbouJd intcrpm the tt$WU 
without unn«e.SAry tq)diliDn. Rcfcn-no:,s to 
rdated studies fflouJd be included in the &m 
""""'· 
In addit:ion. the folluwing $bould be OOk"rflll'd: 
• The full &crm fur •·him an abbr"iation 
stands ~d beus<d al its fust occtll'· 
rmoc in the tat unlcu it is a sb.ndard 
uni1 of mcu'Ul'e The abbn-viation should 
appear in pan-nthcscs after th.e fuU term. 
Abbn-viations .mould not be in the title, 
figure lqi_cnds Ot ul,le titles. 
• FOf stand.ud Ameria.n units, do not USC 
vwcs W.t ate mote signifia..nl tb:an J'OW' 
:anal:,,is is capable of :ao:uratdy meu-ur. 
ing (e.g.. PlillOl 8111 ton 111.2 kPal. not 
83.7tort) . 
• lic:modyiwnic mcuurffl!fflts lot p~urc 
(e.g.. MAP) .d,,uwd alPf"N" in mm Hg and 
gu &cNiun meu=mts (e.g.. Po,) fflould 
appear in turr with SI units in potmtbcscs. 
The units of vasadar Rl!Uta:noe arc dyne. 
"'1aoS. 
• Pbsc p,ovidc r vallX'S (o, parametric data. 
~ts. Al rdcn:nca sbould be cited in 
.k'qucntial otder in th.e tat :and 1ypecl on al 
.$Cpilntc ,beet of ~ · Rdi-tmo:s fflould be 
identified in &al. table.c. and legmcls by fuU • 
.Qu Arabic numcrah o.n th.e rin.e and in paten. 
thcscs. Do not us,c, wordp,oo:,w;ing foc,tnot.,:. 
c:ndnutc. or puignpb numbering funct:io.ns 
to male a lisa of tdetm0!$. Titles of joumak 
~d be sd in iu lia and abbn-viated ac. 
cording to th.e $tyk u:scd in Jnat'x Mtdiau. If 
journal tit.b ue not !isled in Jltleb Mtdinu: 
they fflouJd be spdkd out. U.n pubfuh,ed dab 
o, pmc,nal a,mm-unicat:ions fflould be noted 
pumthdially within th.e Im bul nc,t in the 
Rdi-mica s«tio.n. lndJsiYi: ~ numbtn 
(e.g., p. 1-10) $00Uld be u:scd »fall tdcrenca 
lined below an, samples of sbnd.ud ,d'e,-,:nc. 
« ~. al a,mpldi: lisaing of td'ttmot'S 
an be lound on the lnt.emat:io.naJ Commit. 
ttt of Medical JoutN.1 Editots Web .Qt,:. 
www.icmjc.org. 
~rd Jownal Ankk Bone RC. lwh.er CJ. 
Cmuntr TP. ct al: Sepsis J;Jnd.romc: A ¥#id 
clinical mtity. Crir C." Md 1939: 17:339-393 
~rd Boo4: with Autlt«x Gvdb. JM, T.;ay. 
lot RW. Kilby R.R. Critical Cue Third Edition. 
Philadelphia. lippino,tt, Williams & Will:iM. 
1996 
~rd Boo4: witlt E.Jiron.: Norma:n u. R.dern 
Sf (Eds}. Mcnb.l Health Cue lot £1dcrly l'ffl.. 
pie. New Votl:, Chutehill Livinp,nc, 1996 
~rd Cb«ptrr iit a &ol: PbiUq,5 SJ. Wbi~ 
Nnl JP: Hypcrtmsion and $ttol:e. 1.n: Hy. 
pmm,;io.n: P.;atbophJ,iolol!)', DiagnOOs and 
M.ul~ W.igl JH. Brmncr BM (Eds). 
S«ond Edition. New \:ork, itiYm Ptci.. 1995. 
pp<l65-1117! 
~rd \o\otb SiWE.l«:tnmic Ainnat: M.u. 
ion OW, Domeier R. Dunham CM. ct :al: 
Ptxtioe ~ guidelines for idc:n. 
tifying oervial $pine injuries following 
tr~ Avulablc :U: http-Jlwww.cut.o,g. 
Aco:sscd July I. 2000 
Jiqlhltio.._ £,qtmium should be cmited u 
nDfffl;I.] tat or u imigff. The usc of ,:qtQtion 
«liton or utilities mar not <n.n¥Crt com:.dly 
during the fflamJ,cript $ubmis.silm pn,oe.115 
a:nd thffl us,c, is diitxrutag,ed. 
D 
r.Jdu "'"" Fiprt'I, The mJmbcr of figures 
and tables sbould be app,optiat.e lot the 
length of th.e manu:saipt. do not usc ~
ous iDus1n1iDns. M.ncriik rq,roduud from 
anutfw.r publiffl,:d SOut'C'.C mus1 be bbel,:d ~ R,r.. 
produoed with pcrm.-io.n From. •.• ~ 1.n ;addi. 
t:io.n, a kticr granting pcrmilllion to rq:irocluu 
the mitcrids From the copyriah1 holder must 
be tteeivied by SCCM wh.m t& ma:nwcripl is 
$Ubmitti:d for t~. If the manuscript is ac. 
cq,ted for publiatiDn. ii will not be able to 
be p'inted un.k,,s;s this pc:rmi-.ion ldtcr bu 
be,,m submitk'd. Adap&ticl figun- or table m,;a... 
t.criah m"UJI be bbdcd ~Adapted with pcrmi~ 
$ion from ••. . ~ Ld tc:u of pcrm.-io.n an: WO 
rcquiti:d for acbpted mu.c:rials. A s;a:mplc of a 
pmnissiun r,c,qucs1 ca:n be found on Editorid 
M.U1.:1~ in the imt.rudiDn .k'Ction. 
DaJdu. 0o not USC bl:. to cmlle tables and do 
not usc uble edillnB. Table building utiltics 
wiD convat. p,oviding tb.n no ¢al imaecs 
wen inJctted. Do not rcitc:tat.e tabular dab 
in the text. J)c, nuc use abbttori.itium in table 
titles. 0o not USC :di apibJ ktic:ts in tlbk 
beadings and tat. J)c, not usc cmlff, decimd 
tab. :and jurtil'ntion o,mmandJ. J)c, not use 
$pl('.CS to .-pu.;atc columns.. llic al single bb. 
not a ~ on either side of th,,: ~ symbol 
Do not underline or dr.;aw lines within tables. 
Fooanotcd information should be td'm-no:d 
using itdicui:d. super,aipt. lower case letters 
(i..,c,.. • ') in alphabdical order (tw:!ing from 
left to right). Avoid lc:ngthy footnotes :and in--
ffl'I cbcripti¥C nMt~ in th.e &c:l{L 
Fiprt'I, 
,t) °"'""' DiJOol """"'* 
I . l.cllm about the pJ,liatic,n nquinments fflr 
Digib.l Artworl:: bttp-JJlinks.Jww.om/fSfMl 
2. Ctutc, .sc:an. and A¥C JOU( :artwork and 
compare JOUT final ligutt to the D;gib.l 
Artwork Cuickline Ch.eddi.d. (below). 
3. Upload C:Kh figure to Ediwial ~ 
in conjunct:ion with )'CKlt manuscript text. 
,ndt,bk,. 
B) Difitiz.l Artwork C.Ciddi.nt Ch«llisl 
Ha,: ue th,,: buic'.s to have in pbu bcmtt $al> 
mitting )'OUt digjtal art 
• Artwork ~d be .l:lvied u .tif or AJ1$ files. 
• Artwork is cmited as th.e :actud .Q:ioc (or 
slightly larger) it wiD appear in the joumtl 
( li> fte!l an idci of th.e ,ix,: im,.g,:s ffloulcl be 
wbc:n th,ey print. sl'udy al copy of the jolll'· 
nal In which you wish to submit. Masun-
th,e artwod: typia]ly shown :and sale ywr 
imag,e to m.nch..) 
• Oop OUI any white Of black spao: $111'• 
rounding the imaec-
• Diag,.;atM. d.t,winp. grapM. a:nd other line 
:art must. be -.mot or savied at :a ,-,lution of 
:U b$l 1200dpi. 
• PbotJ>g,aphs. radic,g,aphs. and other half. 
UIC imap muJI be savied .ii. :a moJutio.n of 
:Ubc300dpi. 
• Photographs and n diographs with text. 
must be sa¥l'd u pu5tscripl or al a ,csoJu.. 
OOn of al !cut 600 dpi.. 
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• Each 6gun must be ,awed and $ubmitted 
u a sqM,nti: 61c. Figwa $bould nut be cm. 
bedded in lM ffl#IU$Cl'ipl text file. 
Remember: 
• Cite 6gu.rcs coru«Uti-dy in JOW' 
minuscripL 
• Number ~ in the figuti: lq;md in lM 
order in •·hith they ate di~ 
• Upload figtu-cs C1D1U«Uti¥dy to th,,: Edito--
rial Ma:n.;ig,:re Web lliit.c :and number 6gut'C'$ 
conJ«Uti'rdy in the OcKription bolt d uring ....... 
I« captii,n5 :and ~ within a figw'll, ~ 
Hdvdia (or Arial) li:inL ir p11U11*. in upper 
¥Id k,_. CUC ldtcB. Radic,gnpbit prim,; mwt 
h.1vc - Cir appliabk) "'" dvi1.y. Cob 
~ will ~y be pub5,bed in 
tbc jc,um.ll l we of cob u 'rical to mu~ the 
.,..... ... .......... ~ .. a k J -~ 11.., ........ ..r........, 
,qwocluctiun. liprel M do not «dorm to 
llie,c j :1i ....... will be .tml back ti> lbc o;ir. 
,e,spmdi .. authot lot~ 
Pigure lcFids ,boulcl ambin mougb in . 
lorm.:ition fur the ffllCkr ti> ~ lM 
ilu4ntion •i thout rderring to the tcn. but 
diould be ooncuc :a:nd Jbould not n-peu in . 
lorm.:ition :already mted in lM w:t. figure 
lq;mds sbowd be typed on :a Mp:&t:at.c paftC. 
Pigurcs must be td'ttm«d .M1quc:ntidy in 
the w:L Autbon mwt :a.um,: ch:atp fu, 
ch:a~ made to figtu-cs after ffl#lusctipt:i ate 
"""""· 
U.itJ pf Mti11nt~ Authors .sbmtld p,ovidc 
units of mcutlffflldll in S J units. Authors 
diould rdi-r to lM Amrrinm Mtdiral Auodil-
tion MwuuJ '1{Styk. li:n.th Edition (p. 787) fu, 
details rcptding SI units bf l:aboratory d:ab. 
u,..,,#pl~. P-roridc in ~ lM 
modd number, nun,: of ffl#lufactw\"r, their 
city, and .mti: or o,untry. lor :aD equipment 
dcscoocd in the papet. 
°"'I NiiMu Only pcric dtug n:amcs should 
be u:scd. Tr.ulcmuk or bt:and names should 
nut be used cxq,t in specific ascs wh.m-th.e 
bnnd n:amc is CSSffl!id IIO ,q,,oduoe or in . 
tcrprd lM rtudy. TbClc cscq,timu should be 
nueed in acwmpmying correpc,nclcno:. The 
m:anu!actutcr with the city, Nt.c. and country 
must be p,ovided fur :any bnnd iwn,e drugs. 
Prnniuiio,u. Ar,y submitied miwials th.it 
- "° i..,.,,......i...,..a (- ad..,.i,,,J) "-copy 
righted pubkations murt be accompmj,:d by 
:a written letter of pcrmilllion from the copf'· 
right h~ . Ao:q,t.cd ma:nwi:ripts wiU be 
ddiyed ir n-y pcrmsions att not on 
61c. A ,ample of :a pcrmilllion ~ an be 
lou:nd on Editorial Mula~ in the instruc-
tion l!Cdiun. 
.S.ppkJffnd.J D;fikrl C:O.k.,,t: Authors 
m:ay submit suppkmmt:aJ digitaJ a,nt.ml to 
mbano: their :anide's lcl(t a:nd to be OJoNicl. 
tted bf onlinc.«ily porting. Sappkmcntal 
digital omtcnt miy indudc the following 
types of omtent: kxl doairnmt:i, g,.ipM. 
bhlcs. hgUml. gnpbia. itluw.uiDns, audio. 
:a:nd 'riclco. Cite :aD .wpplcmcntal digitaJ om-
t.ml CO!l$CCwvdy in the t.c:ct. Cibtions ihould 
include the type cf m.ncri:aJ submitt.cd, should 
be dNrlr l:abclcd as "Supplcmc:ntal Digital 
Cunt.mL~ diould indudc a ~ucnlial num. 
be,,, and should provide a brid' dcKriptiDn of 
the $t1pplcmmtaJ omtent. Ptowiclc a lqmd of 
$upplcmcntal digital omtental lM c:nd cf the 
t.c:ct. lilt each legend in th,,: order in which the 
mataial is c:it.cd in the t.crt The ~s must 
be numbered to m.:11di the c:iutiuns fioin the 
t.c:ct. Include a title :and a brief $timmllt)' or the 
ClllfflfflL For ;audio :and video 6Jcc. alJO indudc 
the autbot name. videogriphcr. puticiplmb. 
lfflglb {minute$). and ~u ( MB). A~ 
~d ..,...- y,,t.cnu·..,.... -" ,,_,_ .,... 
t:icnu' n;arnes &om suppkmmt:aJ digital om. 
I.ml unbs thq obuin wrium a,ru,:nt from 
the pat:knU :and $ubmit writien CIIHUcnl with 
the m:amai:ript. Q,pyrigbt :and P-crmiuion 
forms fo, utidc commt including supple. 
mental diitita] omtcnt must be a,mplct.cd :al 
the lime J submi-,n. 
S11pplnna.t11J m1it•l Co1d r.n.t Siu 1111tl Fil" 
T!P' Rt,pfrl!..wrts: Tomaui: a qu.ility ape,-
rien« for UIOIIC viewing $11.pplcmmt:aJ digjtaJ 
amt.em. it is suggested th:at authors submit.-
$Upplm,,mtal digital 6lcs no b.tgcr th:a:n I 0 
MB cub. Docurnenu.111.;i.pb$, and tables may 
be p~.ti:d in :a:ny t'.oimit. F',gu.ta. gnphia. 
:and illusttatiuns $boulcl be submitted with 
the folkiwing hie atcnsions: .ti(. .cps • . ppL 
.itg. .pd{ • . gj{ Audio files ,bou)d be submit.-
t.cd with th,,: folJow.i ng hk alclUiuns: .mpl. 
• wm,;a.. Video lilcs $boulcl be $ubmitted with 
the following file c:umsions: . wmv, .fflO'f', .qL 
.mpg. . .mpcg..mpt. V'.dco files fflCKllcl also be 
formnti:d with a 320 ,: 240 pad minimum. 
Kn'C!I me Fa, mutt infomwilln. pleuc 
review LWW' s rcqui.mncms for submitting 
$Upplm,,mtal digit:aJ a,nt.ent: bttp:/llinb. 
lww.cum/Al42. 
MANUSCRIPT CATEGORIES 
Cuiddines fut the mDSl rttqllfflt lTJ)CS of :arti. 
des .dimitti:d to the jourmJ UC .wmmllfiud 
bdow. 
c..1ill'kal l•~t»-These indudc t~ ;_, _,,_.kd 1,-;.~ I ~ ..,., 
,cb...p«liot saudics.amongothcn.. With.in thil 
CUlgOfy, WC aho fe..:ihlt< fuur ~ at.-
qprics incb!inp; Catdilc lnDerui¥C Cate. N,:o. 
.wt:al lnDerui¥C Utt. ~ Cuc. :and 
Qwlity and Sady. This atqpty of m:unacripl 
bu a word limit of 200> to 400> wonts (~ 16 
typed ~ p,:lft.CI) which indudcs :a:n 
abstraca of ni1 1MtC than 300 word,. the Di~ 
awion ..aion or the ffl#IU!la'ipl should be 
limited IIO no more than 1500 wonk :a ffllli. 
ID 
mum of 40 Mct'fflt'.1:$; :and no matt th:an 7 Pig.-
ure..: ancl/or T.cablcs. 
i..l,«,r""7 l,1watipJKIW. The,e, include bbcira.-
tory ;m animal~ This ~of m;m. 
uscript has a word limit of ~ IIO «KXI wcJtds 
(8-16typol _ _,....., ........... 
an amtr:ad J no mDt< than JOO ~ the JM.. 
cus.sic,n ,i:aion cf the tNtlWCripl ,bouJd be b-
illed ti> no more 1ml 1.500 WCltcb; a muimum cf 
40 ttf.:ttna,; :and no mote than 7 Fig&RS and/ 
«TohloL 
ktWW NtidN. These o:nu:isa of aitial -. 
mc:nt cf ltcJ..uutc :and d:ib ~ng ti> din.. 
al q.io.ln f'ffll:.'1" :attickJ. cmpb;uil should be 
pbad on ~ diap,,ic. thcnpy. prognociis. 
:md prcwmtion. ~~8 the 
type of ,tudy or Ry.sis. pc,pubtii:an. imo,m.. 
ti!,n. :md OllltllmC: should be included fDt- :al 
d.aia med. lbe ~ proass UICd for :al = should be dcu:tibcd M«a..:an;,ly,cs will be 
~ as l'ffleW p,:tpcn.. The~ 
lmglh of f'ffll:_'1" artidcs l$ ~ ti> 3<XX) wcJtds 
(~ 12 l')pCld ~ J)l"lfl'S) •·hich in. 
dudes an ab.tr:act J no fflOi'C thm JOO WOW$; :a 
muim1rn or 100 ~ :and no iMtC thm 
10 Pigtam; a:ndfor nbb 
Brief &pc,rr,. TbClc should be short nports 
or onginaJ sauc1aes CH' c,orawt:iom. The,_ 
mended lmgth cf brief reports U ni1 mon! 
than 1500 wotds (6 typed doublc-spao:d 
~ which incbks :an :abttaa of no mon! 
than JOO won1,. :a muimum or 25 tcfer~ 
and no mo,c tb:an 2 Figure :and/CH' Tables. 
J'a'3f l'...pt..tiMG. Thccc indud,: attidcs Wit 
m:ay &II owidc the Rlllm d li:anml diniaJ ot 
b.uic $clenoe tcSeltCh,. such • MlCi:al polcy. pro. 
li:sioml ~cthiaJ dlemmu. :md dcliv. 
tty of o,mpuirion.itc ate The 1m,a1101dcd 
knglbisni1mDttlb:a:n IS00wonk(6 t}'peddou.-
1*'4paad pages) which incblcs :a:n abttaa cf 
no mote tlun 300won:k a mas:imumcf2S iffl:t. 
c:no:,s and no mote tbm 4 Pigwo a:ndfor Tllbb. 
Eridni«-&aml Jo.,m.J 0 .11ft. TbClc articles 
pm'riclc :a:n criclcno:-bucd critique or a tt'Cffll 
important p:apcr in the fide! or pediatric a iti. 
c:al an medicine. The n,commmded length 
is ni1 mute th:an 1500 words (6 typed doubb 
$pao:d 1M£<$) which i.didcs an abw.ict of 
no mute than JOO words; a maximum of 25 
rd'crenais: :a:nd no mute than 4 Figures :and/ 
ruTobb 
Lrctt.rn • Ml<- !Ji-. Lc.1-.:u '° tl,., &ii- • tc 
c:no,ur~ Letters ffltJSI specifically :addtt,;s 
a tteent utidc published in Ptdi..trir CriJiaal 
C..n' Mdidnt. They should be no mote than 
500words( 2 l}'pc,d ~ pap) with 
a muimtlffl or 5 tcfcn:nais. 
I irvilm Edifrrid. Tbcsc ,q,reser1t a,mmerrtarics 
add.csing newly publsbcd artidcs in the jc,w. 
.w.l and ate by inritalii:l!I only. !milled «lit«ials 
should be ni1 mote thin I~ WCJtds (S typed 
	  




Al manwaipt5 wil be ~ by £ditDrid 
Bnatd members or onnilturts ,ck,cted by the 
editor.in-dud. Initial cdiloM ~ u,,a;ady 
;,n, a,mpl,:.vd within a.10 wccbof ~
~ The time mp;aiml lo, fl."¥iew of ~ 
Yi,c,d mmmcripb is YUiablc. 
ACCEPTANCE 
AD information rqptding the uapt«l ma:n.u.-
.$Cl'ipt and its publiation date :an-comidcntid. 
No information rqptding the mamJKripc an 
appcu in print. on the tdevifiun or twio. « 
in any ckctnmk form until the day bcfott its 
publiatiun date. It ammt b,: tdeucd to th.e 
meclA until the dir bcfo~ the publiation 
"""-
Pennissio,u 
For pcrmisirion :and/« rights to use Clllfflfflt 
for which the a,py, igbt hoJck.r is the Soc:idy 
of Critical Cuc ~cine or LWW, p1cue Bl> 
to th.e journal's Web ate and after d icking 
on lM tdcnn.t article, dick cm the ~Request 
PffmiJAonS link under the "Artide T()(lls" 
box that appears on the right $iclc of tbe 
~ Altermtivdy. .-nd :an c-miil to 
customcru~ptrigbt.a,m. 
For Ttuubtion Rights & liuming qucrie5. 
contxt Sitvia Sau , Ttarubtiuns Righb. 
UCC!Uing & PcrmiSAOnS M.m~. Wolters 
Kluwer Hei!th (M«lieiJ Research) l td. 
250 Waterloo RtNd, Lc,ndon SEI 8RD. 
UK. Phone +44 (0) 1JJ7 981 0600. Emiil: 
$ilvi.ucrn.holicr51.Juwer.com. 
For Spc,ciiJ Projffls and Reprints ( U.5./0an. 
;acb), contact Alu! Moot-c. Oir«tor of~ 
Uppina,u Williams & Wilkins. Two Com. 
mcru SqUMc, 2001 M.ukt't St.tNt. Pbibdd. 
phia, PA 19103. Phone: l lS..521-8638.. Em,;i.il: 
alan.ffl()(lt~luwer.CIUffl.. 
For Special Proj«u :and Reprints (non. 
U.S.IC&nada) . contact Sil-ria Sern. Tram. 
lations Righu. Liuruing & PcnniMiuns 
Mana11tr, Woltt:rs KluWtt licaltb (Medical 
IV 
R.eileuch) Ltd. 250 Wiit.crloo Rmd. Lc,ndon 
SEI 8RO, Ul.. Phone: -+44 (0) 1:07981 0600. 
E-mail: s.iM..ucrraEPwoltcrd:luwu.com. 
REPRINTS 
Rcprint:s an, a'r'aibbk fuw-~ after the 
publicat:ion of th.t jm,mal th.tough th.t Put> 
lidlcr. Fol information and pricec. all (800) 
34l-22S3or E-mail to rcprint,&tww.com. 
CONTACT 
QuertionJ ~gatding the Alltus of submitted 
mamixripts a~ best ansWIC'f'ed by logging on 
to the PAQJ«tion of Editorial Manage,4. The 
assigned mmwcript number ,.; 11 aluw au. 
thor:s to YK'W the Ntus of tlwir mamJ,cripc. ff 
authors need additioiw.1 inrc,rm;uii,n ~gatd. 
ing a mfflWIC'.ript. plcue .-ncl an e-mail to 
~Of! and include )'OU! manu.-
.$Cl'ipt number in th.t ttqUffi. o, call (847) 
827--6869 Muncbr through Frid.:iy. from 0800 
to 1700, Cmtral Sta:ndatd Time. 
Gortupc,ud,;;'" can alco be sent tuc 
htrid: M.. Koch;,.n,:k. MD. MCX:M 
Editor, Pdi«tric Cril.iesl C.,.. M~ 
Soc:idy or Critical Cuc Medicine 
500 M:ictw:iy Ori¥C 
Ml. Prospect. IL 60056 
